amphetamine has been researched along with Dementia Praecox in 349 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recent work suggests that the amphetamine sensitization model of schizophrenia can safely be induced in healthy volunteers and is associated both with behavioral and dopaminergic hypersensitivity to amphetamine." | 9.15 | Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. ( Joyce, D; Murray, RM; O'Daly, OG; Shergill, SS; Stephan, KE, 2011) |
| "D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia." | 9.11 | Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. ( Barch, DM; Carter, CS, 2005) |
| "Recent brain imaging studies have indicated that schizophrenia is associated with increased amphetamine-induced dopamine release in the striatum." | 9.09 | Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. ( Abi-Dargham, A; Carlsson, A; Cooper, TB; Kegeles, LS; Laruelle, M; Mann, JJ; Rodenhiser-Hill, J; Van Heertum, RL; Zea-Ponce, Y, 2000) |
| "The purpose of this study was to assess further the effect of amphetamine on negative symptoms of schizophrenia." | 9.08 | Amphetamine and negative symptoms of schizophrenia. ( Angrist, B; Cooper, TB; Duncan, E; Peselow, ED; Rotrosen, J; Sanfilipo, M; van Kammen, DP; Wieland, S; Wolkin, A, 1996) |
| "Preliminary evidence suggest clozapine is associated with more favorable impact on concurrent substance use disorder related outcomes in patients with concurrent schizophrenia spectrum disorders (SSD)." | 8.31 | Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study. ( Bousman, CA; Danilewitz, M; Frankow, L; Honer, WG; Mahmood, H; Mathew, N; Poonia, S; Rafizadeh, R; Schütz, CG, 2023) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 8.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "We measured cell distribution in striatum and cortex by histology and microtomography, and quantified the basal and amphetamine-stimulated locomotion and nuclear-distribution element-like 1 activity (in blood and brain) of transgenic disrupted-in-schizophrenia 1 rat vs wild-type littermate controls." | 7.96 | Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity. ( Cruz, FC; Dias, CS; Engi, SA; Fonseca, MC; Gazarini, ML; Hayashi, MA; Korth, C; Nani, JV; Perillo, MG, 2020) |
| " These issues arise in studies in which the psychostimulant, amphetamine, is used as an Experimental Medicine probe in patients with schizophrenia." | 7.91 | Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients. ( Benster, L; Bhakta, SG; Kotz, J; Lavadia, M; Light, GA; Swerdlow, NR; Talledo, J, 2019) |
| "Nicotine use and dependence is very high in patients with schizophrenia." | 7.88 | Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress? ( Coen, KM; Fletcher, PJ; Lê, AD; Li, Z, 2018) |
| " We now report the effects of the pro-attentional drug, d-amphetamine, on PPI and neurocognition in antipsychotic-medicated schizophrenia patients and healthy subjects (HS) who were also tested in a targeted cognitive training (TCT) module." | 7.88 | Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. ( Bhakta, SG; Franz, DM; Hughes, EL; Light, GA; Rana, BK; Swerdlow, NR; Talledo, JA, 2018) |
| "Receptor imaging studies have reported increased amphetamine-induced dopamine release in subjects with schizophrenia (SCH) relative to healthy control subjects (HCs)." | 7.88 | Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. ( Frankle, WG; Himes, M; Mason, NS; Mathis, CA; Narendran, R; Paris, J, 2018) |
| "This study examines whether illicit amphetamine use is associated with differences in the prevalence of specific psychiatric symptoms in a community sample of individuals diagnosed with schizophrenia or affective psychotic disorders." | 7.88 | The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses. ( Burns, R; Calabria, B; Castle, D; McKetin, R; Voce, A, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 7.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "We investigated transition from amphetamine-induced psychosis (AIP) to schizophrenia." | 7.81 | Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. ( Bramness, JG; Gossop, M; Holm, B; Medhus, S; Mørland, J; Rognli, EB, 2015) |
| "To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia." | 7.80 | Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014) |
| "Perturbation of Disrupted-In-Schizophrenia-1 (DISC1) and D-serine/NMDA receptor hypofunction have both been implicated in the pathophysiology of schizophrenia and other psychiatric disorders." | 7.79 | Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. ( Abazyan, B; Abazyan, S; Ma, TM; Nomura, J; Pletnikov, MV; Sawa, A; Seshadri, S; Snyder, SH; Yang, C, 2013) |
| "We measured the expression of D2Rs dimers and monomers in patients with schizophrenia using Western blots, and then in striatal tissue from rats exhibiting the amphetamine-induced sensitized state (AISS)." | 7.76 | Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. ( Fletcher, PJ; Kapur, S; Liu, F; Pei, L; Seeman, P; Wang, M, 2010) |
| " D1-D2 heteromer sensitivity and functional activity was up-regulated in rat striatum by chronic amphetamine treatment and in globus pallidus from schizophrenia patients, indicating that the dopamine D1-D2 heteromer may contribute to psychopathologies of drug abuse, schizophrenia, or other disorders involving elevated dopamine transmission." | 7.76 | The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. ( Alijaniaram, M; Fan, T; Fletcher, PJ; George, SR; Hasbi, A; O'Dowd, BF; Perreault, ML; Seeman, P; Varghese, G, 2010) |
| " As this is a similar profile to that observed in the CNS from subjects with schizophrenia, we examined whether postmortem CNS tissue from subjects with the disorder and brain striata from an animal model of psychosis or schizophrenia (the amphetamine-sensitized rat) had altered levels of RGS9-2." | 7.74 | Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. ( Dean, B; Greenstein, R; Jack, E; Ko, F; Seeman, P, 2007) |
| "Based on the 'endogenous dopamine sensitization' hypothesis of schizophrenia the present study employed a repeated amphetamine administration regime in order to investigate the behavioral, neurochemical and neuroanatomical consequences following short- and long-term withdrawal periods." | 7.74 | Amphetamine sensitization in rats as an animal model of schizophrenia. ( Feldon, J; Knuesel, I; Peleg-Raibstein, D, 2008) |
| " The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice." | 7.73 | Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005) |
| "As a test of plausibility for the hypothesis that schizophrenia can result from abnormal brain, especially cerebral cortical, development, these studies examined whether, in the rat, disruption of brain development initiated on embryonic day (E) 17, using the methylating agent methylazoxymethanol acetate (MAM), leads to a schizophrenia-relevant pattern of neural and behavioral pathology." | 7.73 | A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. ( Geyer, MA; Ghajarnia, M; Grace, AA; Jentsch, JD; Moore, H, 2006) |
| "The aim of these studies was to examine whether amphetamine-induced sensitization in rats could be used as an animal model to study the basis of certain abnormalities seen in schizophrenia." | 7.72 | Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. ( Fletcher, PJ; Kapur, S; Tenn, CC, 2003) |
| "The usefulness of 123I-epidepride as a single photon emission computed tomography (SPECT) scan D2 receptor ligand was examined in vivo in 13 medicated patients with schizophrenia and age- and sex-matched normal controls." | 7.69 | A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls. ( Golberg, K; Joshua, A; McEwan, AJ; Scott, J; Silverstone, PH; Tibbo, P, 1997) |
| "A major line of evidence that supports the hypothesis of dopamine overactivity in schizophrenia is the psychomimetic potential of agents such as amphetamine that stimulate dopamine outflow." | 7.69 | Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. ( Breier, A; Carson, RE; de Bartolomeis, A; Eckelman, WC; Kolachana, BS; Malhotra, AK; Pickar, D; Saunders, R; Su, TP; Weinberger, DR; Weisenfeld, N, 1997) |
| "A 19-year-old man developed a schizophrenia-like psychosis after ingesting isosafrole." | 7.67 | Isosafrole and schizophrenia-like psychosis. ( Haier, RJ; Keitner, GI; Sabaawi, M, 1984) |
| " Clinical evidence suggests that a similar agonist-induced hypersensitivity may play a role in the development of dyskinetic movement disorders and psychoses in humans following the chronic use of such dopamine agonists as amphetamine and levodopa." | 7.65 | Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders. ( Klawans, HL; Margolin, DI, 1975) |
| "If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia." | 6.84 | Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. ( Alvarez, AI; Bhakta, SG; Hughes, EL; Light, GA; Rana, B; Swerdlow, NR; Talledo, J; Tarasenko, M; Vinogradov, S, 2017) |
| "Schizophrenia is a serious psychiatric disorder which impacts a broad range of cognitive, behavioural and emotional domains." | 6.44 | The amphetamine-induced sensitized state as a model of schizophrenia. ( Featherstone, RE; Fletcher, PJ; Kapur, S, 2007) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 5.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| " Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis." | 5.40 | A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. ( Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 5.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Schizophrenia is a disease typically associated with an adolescent onset." | 5.40 | An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia. ( Chen, L; Lodge, DJ; Perez, SM, 2014) |
| "Schizophrenia is believed to arise from an interaction of genetic predisposition and adverse environmental factors, with stress being a primary variable." | 5.39 | Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. ( Du, Y; Grace, AA, 2013) |
| "Amphetamine pretreatment induced behavioral sensitization in both rat strains similarly." | 5.35 | The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? ( Feldon, J; Hauser, J; Peleg-Raibstein, D; Yee, BK, 2009) |
| "Schizophrenia is a neuropsychiatric disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 5.35 | Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. ( Assaf, Y; Piontkewitz, Y; Weiner, I, 2009) |
| " In the present experiment, prefrontal acetylcholine (ACh) release was measured in attentional task-performing and non-performing rats pretreated with an escalating dosing regimen of amphetamine (AMPH) and following challenges with AMPH." | 5.34 | Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. ( Brown, H; Bruno, JP; Kozak, R; Martinez, V; Sarter, M; Young, D, 2007) |
| "Schizophrenia is characterized by severe abnormalities in cognition, including disordered attention." | 5.32 | Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia. ( Grottick, AJ; Higgins, GA; Le Pen, G; Moreau, JL, 2003) |
| " Our computational results mirror our empirical study of dopamine modulation in schizophrenia and healthy controls, which showed that amphetamine administration increased gamma power in patients but decreased it in controls." | 5.16 | Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies. ( Bard Ermentrout, G; Cho, RY; Kömek, K; Walker, CP, 2012) |
| "Recent work suggests that the amphetamine sensitization model of schizophrenia can safely be induced in healthy volunteers and is associated both with behavioral and dopaminergic hypersensitivity to amphetamine." | 5.15 | Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. ( Joyce, D; Murray, RM; O'Daly, OG; Shergill, SS; Stephan, KE, 2011) |
| "D-Amphetamine improved reactions times on the spatial working memory and Stroop tasks for both individuals with schizophrenia and controls, and improved working memory accuracy in schizophrenia." | 5.11 | Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. ( Barch, DM; Carter, CS, 2005) |
| "Recent brain imaging studies have indicated that schizophrenia is associated with increased amphetamine-induced dopamine release in the striatum." | 5.09 | Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. ( Abi-Dargham, A; Carlsson, A; Cooper, TB; Kegeles, LS; Laruelle, M; Mann, JJ; Rodenhiser-Hill, J; Van Heertum, RL; Zea-Ponce, Y, 2000) |
| "The purpose of this study was to assess further the effect of amphetamine on negative symptoms of schizophrenia." | 5.08 | Amphetamine and negative symptoms of schizophrenia. ( Angrist, B; Cooper, TB; Duncan, E; Peselow, ED; Rotrosen, J; Sanfilipo, M; van Kammen, DP; Wieland, S; Wolkin, A, 1996) |
| " Second, we review the studies that have examined latent inhibition in populations with schizophrenia and in healthy populations after administration of amphetamine or haloperidol." | 4.88 | The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)? ( Le Pelley, M; Schmidt-Hansen, M, 2012) |
| "Preliminary evidence suggest clozapine is associated with more favorable impact on concurrent substance use disorder related outcomes in patients with concurrent schizophrenia spectrum disorders (SSD)." | 4.31 | Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study. ( Bousman, CA; Danilewitz, M; Frankow, L; Honer, WG; Mahmood, H; Mathew, N; Poonia, S; Rafizadeh, R; Schütz, CG, 2023) |
| "Pretreatment with EECL demonstrated antipsychotic activity in mice, preventing amphetamine-, apomorphine-, and ketamine-induced schizophrenia-like symptoms, with 800 mg/kg being the most effective dose." | 4.12 | Pretreatment with Carpolobia lutea ethanol extract prevents schizophrenia-like behavior in mice models of psychosis. ( Abdulrahim, HA; Aderibigbe, AO; Bakre, AG; Ben-Azu, B; Ezurike, PU; Isibor, H; Omeiza, NA; Sowunmi, AA, 2022) |
| "In the suited rat-models, we focused on the stable pentadecapeptide BPC 157, L-NAME, NOS-inhibitor, and L-arginine, NOS-substrate, relation, the effect on schizophrenia-like symptoms." | 4.02 | Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia. ( Balenovic, I; Blagaic, AB; Cilic, M; Drmic, D; Filipcic, I; Ilic, S; Kokot, A; Seiwerth, S; Sikiric, P; Strbe, S; Tvrdeic, A; Vukojevic, J; Zemba Cilic, A; Zemba, M; Zoricic, Z, 2021) |
| "Cannabidiol (CBD), a major non-psychotomimetic component of the Cannabis sativa plant, shows therapeutic potential in several psychiatric disorders, including schizophrenia." | 4.02 | Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. ( Crippa, JAS; Del Bel, E; Guimarães, FS; Joca, SRL; Pedrazzi, JFC; Sales, AJ, 2021) |
| "We measured cell distribution in striatum and cortex by histology and microtomography, and quantified the basal and amphetamine-stimulated locomotion and nuclear-distribution element-like 1 activity (in blood and brain) of transgenic disrupted-in-schizophrenia 1 rat vs wild-type littermate controls." | 3.96 | Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity. ( Cruz, FC; Dias, CS; Engi, SA; Fonseca, MC; Gazarini, ML; Hayashi, MA; Korth, C; Nani, JV; Perillo, MG, 2020) |
| "Here, we tested whether amphetamine would similarly improve 5C-CPT performance in the presence of dopamine D2 receptor blockade, since pro-cognitive treatments in schizophrenia would virtually always be used in conjunction with D2 receptor antagonists." | 3.96 | Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. ( Breier, M; Roberts, BZ; Swerdlow, NR; Young, JW, 2020) |
| " These issues arise in studies in which the psychostimulant, amphetamine, is used as an Experimental Medicine probe in patients with schizophrenia." | 3.91 | Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients. ( Benster, L; Bhakta, SG; Kotz, J; Lavadia, M; Light, GA; Swerdlow, NR; Talledo, J, 2019) |
| "Amphetamine-induced augmentation of striatal dopamine and its blunted release in prefrontal cortex (PFC) is a hallmark of schizophrenia pathophysiology." | 3.91 | Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction. ( Belforte, JE; Diaz, NB; Eskow Jaunarajs, KL; Fujita, Y; Hashimoto, K; Jeevakumar, V; Jiang, SZ; Nakao, K; Nakazawa, K; Pretell Annan, CA, 2019) |
| "Nicotine use and dependence is very high in patients with schizophrenia." | 3.88 | Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress? ( Coen, KM; Fletcher, PJ; Lê, AD; Li, Z, 2018) |
| "The methylazoxymethanol acetate (MAM) rodent neurodevelopmental model of schizophrenia exhibits aberrant dopamine system activation attributed to hippocampal dysfunction." | 3.88 | Impaired contextual fear-conditioning in MAM rodent model of schizophrenia. ( Gill, KM; Grace, AA; Miller, SA, 2018) |
| " We now report the effects of the pro-attentional drug, d-amphetamine, on PPI and neurocognition in antipsychotic-medicated schizophrenia patients and healthy subjects (HS) who were also tested in a targeted cognitive training (TCT) module." | 3.88 | Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients. ( Bhakta, SG; Franz, DM; Hughes, EL; Light, GA; Rana, BK; Swerdlow, NR; Talledo, JA, 2018) |
| "Receptor imaging studies have reported increased amphetamine-induced dopamine release in subjects with schizophrenia (SCH) relative to healthy control subjects (HCs)." | 3.88 | Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia. ( Frankle, WG; Himes, M; Mason, NS; Mathis, CA; Narendran, R; Paris, J, 2018) |
| "This study examines whether illicit amphetamine use is associated with differences in the prevalence of specific psychiatric symptoms in a community sample of individuals diagnosed with schizophrenia or affective psychotic disorders." | 3.88 | The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses. ( Burns, R; Calabria, B; Castle, D; McKetin, R; Voce, A, 2018) |
| " Some dimensions of the schizophrenia syndrome in man can be mimicked in animals by the amphetamine (AMPH)-sensitization-induced psychosis model." | 3.88 | Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats. ( Dere, E; Grömer, TW; Kornhuber, J; Müller, CP; Schindehütte, M; Uzuneser, TC; von Hörsten, S, 2018) |
| "Considering that ligands of metabotropic glutamate and GABA receptors may exert beneficial effects on schizophrenia, we assessed the actions of the first mGlu>4-selective orthosteric agonist, LSP4-2022, in several tests reflecting positive, negative, and cognitive symptoms of schizophrenia." | 3.83 | Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022. ( Acher, F; Gruca, P; Lasoń-Tyburkiewicz, M; Marciniak, M; Papp, M; Pilc, A; Wierońska, JM; Woźniak, M, 2016) |
| "To (1) test amphetamine-induced dopamine release in the dorsolateral PFC (DLPFC) in drug-free or drug-naive patients with schizophrenia (SCZ) and healthy control (HC) individuals matched for age, sex, race/ethnicity, and familial socioeconomic status;(2) test blood oxygenation level-dependent (BOLD) functional magnetic resonance imaging activation during a working memory task in the same participants; and (3) examine the relationship between positron emission tomographic and functional magnetic resonance imaging outcome measures." | 3.81 | Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. ( Abi-Dargham, A; Carson, RE; D'Souza, D; Gil, R; Girgis, R; Hackett, E; Huang, Y; Lieberman, JA; Lim, K; Malison, RT; Moore, H; Nabulsi, N; Narendran, R; Ojeil, N; Slifstein, M; Thompson, JL; van de Giessen, E; Van Snellenberg, J, 2015) |
| "Gestational day 17 methylazoxymethanol (MAM) treatment has been shown to reproduce, in rodents, some of the alterations in cortical and mesolimbic circuitries thought to contribute to schizophrenia." | 3.81 | MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function. ( Howe, WM; Kozak, R; Oomen, C; Tierney, PL; Young, DA, 2015) |
| "We investigated transition from amphetamine-induced psychosis (AIP) to schizophrenia." | 3.81 | Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. ( Bramness, JG; Gossop, M; Holm, B; Medhus, S; Mørland, J; Rognli, EB, 2015) |
| "To examine the effects of dehydroepiandrosterone (DHEA) on animal models of schizophrenia." | 3.80 | Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice. ( Kilic, FS; Kulluk, D; Musmul, A, 2014) |
| "Perturbation of Disrupted-In-Schizophrenia-1 (DISC1) and D-serine/NMDA receptor hypofunction have both been implicated in the pathophysiology of schizophrenia and other psychiatric disorders." | 3.79 | Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion. ( Abazyan, B; Abazyan, S; Ma, TM; Nomura, J; Pletnikov, MV; Sawa, A; Seshadri, S; Snyder, SH; Yang, C, 2013) |
| "We have shown previously that aberrant hippocampal (HPC) output underlies the dopamine (DA) dysfunction observed in the methylazoxymethanol acetate (MAM) developmental model of schizophrenia in the rodent." | 3.77 | A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia. ( Aras, S; Cook, JM; Gill, KM; Grace, AA; Lodge, DJ, 2011) |
| "We measured the expression of D2Rs dimers and monomers in patients with schizophrenia using Western blots, and then in striatal tissue from rats exhibiting the amphetamine-induced sensitized state (AISS)." | 3.76 | Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization. ( Fletcher, PJ; Kapur, S; Liu, F; Pei, L; Seeman, P; Wang, M, 2010) |
| " D1-D2 heteromer sensitivity and functional activity was up-regulated in rat striatum by chronic amphetamine treatment and in globus pallidus from schizophrenia patients, indicating that the dopamine D1-D2 heteromer may contribute to psychopathologies of drug abuse, schizophrenia, or other disorders involving elevated dopamine transmission." | 3.76 | The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia. ( Alijaniaram, M; Fan, T; Fletcher, PJ; George, SR; Hasbi, A; O'Dowd, BF; Perreault, ML; Seeman, P; Varghese, G, 2010) |
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | 3.75 | BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "Ketamine-induced alterations in EEG power spectra are consistent with abnormalities in the theta and gamma frequency ranges reported in patients with schizophrenia." | 3.75 | N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia. ( Contreras, D; Ehrlichman, RS; Finkel, LH; Gandal, MJ; Lazarewicz, MT; Maxwell, CR; Siegel, SJ; Turetsky, BI, 2009) |
| "Previous studies demonstrated increased striatal dopamine (DA) release after amphetamine challenge and increased striatal baseline occupancy of D2 receptors in patients with schizophrenia compared with control subjects." | 3.75 | Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. ( Abi-Dargham, A; Kegeles, LS; Laruelle, M; Slifstein, M; van de Giessen, E, 2009) |
| " The known PPI-enhancing effect of the antipsychotic, clozapine, was then evaluated in half of the animals, whilst the other half was subjected to two additional schizophrenia-relevant behavioural tests: latent inhibition (LI) and locomotor reaction to the psychostimulants-amphetamine and phencyclidine." | 3.75 | Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. ( Feldon, J; Singer, P; Yee, BK, 2009) |
| "To establish a primate animal model of schizophrenia with negative symptoms, the behavioral effects of chronic phencyclidine (PCP) and additional acute methamphetamine (MAP) administration were investigated in six monkeys." | 3.74 | A primate model of schizophrenia using chronic PCP treatment. ( Hori, E; Maior, R; Maior, RS; Mao, CV; Nishijo, H; Ono, T, 2008) |
| " As this is a similar profile to that observed in the CNS from subjects with schizophrenia, we examined whether postmortem CNS tissue from subjects with the disorder and brain striata from an animal model of psychosis or schizophrenia (the amphetamine-sensitized rat) had altered levels of RGS9-2." | 3.74 | Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. ( Dean, B; Greenstein, R; Jack, E; Ko, F; Seeman, P, 2007) |
| "Based on the 'endogenous dopamine sensitization' hypothesis of schizophrenia the present study employed a repeated amphetamine administration regime in order to investigate the behavioral, neurochemical and neuroanatomical consequences following short- and long-term withdrawal periods." | 3.74 | Amphetamine sensitization in rats as an animal model of schizophrenia. ( Feldon, J; Knuesel, I; Peleg-Raibstein, D, 2008) |
| " The aim of this study was to evaluate the effect of subchronic caffeine treatment on MK-801-induced hyperlocomotion, ataxia and cognitive deficits, as well as amphetamine-induced hyperlocomotion in mice." | 3.73 | Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice. ( Dall'Igna, OP; de Oliveira, RV; Lara, DR; Neto, PF; Santos Gomes, MW; Schuh, JF; Souza, DO; Tort, AB, 2005) |
| " A young alcohol abuser was referred to the Acute Poisonings Unit at Wrocław with a presumptive diagnosis of methanol poisoning." | 3.73 | Poisoning or primary nervous system disease?--difficulties of the differential diagnosis exemplified by four different clinical cases. ( Antończyk, A; Kochman, K; Magdalan, J; Porebska, B, 2005) |
| "As a test of plausibility for the hypothesis that schizophrenia can result from abnormal brain, especially cerebral cortical, development, these studies examined whether, in the rat, disruption of brain development initiated on embryonic day (E) 17, using the methylating agent methylazoxymethanol acetate (MAM), leads to a schizophrenia-relevant pattern of neural and behavioral pathology." | 3.73 | A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. ( Geyer, MA; Ghajarnia, M; Grace, AA; Jentsch, JD; Moore, H, 2006) |
| " Amphetamine-induced disruption of LI and its potentiation by antipsychotic drugs (APDs) in the adult rat are well-established models of schizophrenia and antipsychotic drug action, respectively." | 3.72 | Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia. ( Rimmerman, N; Weiner, I; Zuckerman, L, 2003) |
| "Repeated amphetamine (AMPH) exposure in nonhuman primates produces a chronic state of monoamine dysregulation and long-lasting changes in behaviors elicited by acute AMPH (including tracking, grasping "at thin air," manipulating nonapparent stimuli, and hypervigilance) in a manner that bears a marked resemblance to symptoms of both amphetamine psychosis and paranoid schizophrenia." | 3.72 | Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates. ( Castner, SA; Goldman-Rakic, PS, 2003) |
| "The aim of these studies was to examine whether amphetamine-induced sensitization in rats could be used as an animal model to study the basis of certain abnormalities seen in schizophrenia." | 3.72 | Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. ( Fletcher, PJ; Kapur, S; Tenn, CC, 2003) |
| "003) in pups born to mothers who were stressed during pregnancy by injections of either saline or amphetamine in saline." | 3.72 | Very mild stress of pregnant rats reduces volume and cell number in nucleus accumbens of adult offspring: some parallels to schizophrenia. ( Ishtoyan, A; Lyon, M; McClure, WO, 2004) |
| "The indirect DA agonist amphetamine has been used to model the auditory sensory processing deficits in schizophrenia." | 3.72 | Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. ( Abel, T; Kanes, SJ; Maxwell, CR; Siegel, SJ, 2004) |
| " In the present study, JL13 was compared with clozapine and haloperidol in several animal models for schizophrenia." | 3.71 | Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia. ( Bruhwyler, J; Cools, AR; Ellenbroek, BA; Liégeois, JF, 2001) |
| "The authors previously observed an increase in striatal dopamine transmission following amphetamine challenge in 15 untreated patients with schizophrenia compared to 15 matched healthy subjects." | 3.70 | Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. ( Abi-Dargham, A; Baldwin, RM; Bowers, M; Charney, DS; Gil, R; Innis, RB; Krystal, J; Laruelle, M; Seibyl, JP; van Dyck, CH, 1998) |
| "Oxytocin plays an important role in the regulation of normal cognitive functions and behaviors, which are disturbed in schizophrenia." | 3.70 | Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. ( Feifel, D; Reza, T, 1999) |
| "Schizophrenia has been linked to abnormal dopamine function, recently to excessive amphetamine-induced release of striatal dopamine, and also to pathology of prefrontal cortical neurons." | 3.70 | The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. ( Adler, C; Bertolino, A; Breier, A; Callicott, JH; Frank, JA; Mattay, VS; Pickar, D; Shapiro, M; Weinberger, DR, 2000) |
| "The enhancement of immobility in a forced swimming test of mice induced by repeated treatment with phencyclidine and amphetamine swimming "normalization" test of mice were used as animal models of negative and positive symptoms of schizophrenia, respectively." | 3.70 | Atypical antipsychotic effects of quetiapine fumarate in animal models. ( Dai, J; Guan, HJ; Zhu, XZ, 2000) |
| "The usefulness of 123I-epidepride as a single photon emission computed tomography (SPECT) scan D2 receptor ligand was examined in vivo in 13 medicated patients with schizophrenia and age- and sex-matched normal controls." | 3.69 | A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls. ( Golberg, K; Joshua, A; McEwan, AJ; Scott, J; Silverstone, PH; Tibbo, P, 1997) |
| "A major line of evidence that supports the hypothesis of dopamine overactivity in schizophrenia is the psychomimetic potential of agents such as amphetamine that stimulate dopamine outflow." | 3.69 | Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. ( Breier, A; Carson, RE; de Bartolomeis, A; Eckelman, WC; Kolachana, BS; Malhotra, AK; Pickar, D; Saunders, R; Su, TP; Weinberger, DR; Weisenfeld, N, 1997) |
| "One hundred ten patients with alcohol dependence and 56 psychiatric patients with either senile dementia, amphetamine psychosis, epilepsy or chronic schizophrenia were investigated with a CT scan of the brain." | 3.68 | Computerized tomographic study on the brain of patients with alcohol dependence. ( Kato, A; Nakajima, T; Nakamura, M; Tsuji, M, 1991) |
| "The animal amphetamine model of schizophrenia has been based primarily on stereotyped behavior." | 3.67 | Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. ( Feldon, J; Lubow, RE; Weiner, I, 1984) |
| "A 19-year-old man developed a schizophrenia-like psychosis after ingesting isosafrole." | 3.67 | Isosafrole and schizophrenia-like psychosis. ( Haier, RJ; Keitner, GI; Sabaawi, M, 1984) |
| "Twenty-one schizophrenic subjects, who had been neuroleptic-free, were tested for responsiveness to dopaminergic agonists: Apomorphine emesis threshold was determined and change in psychopathology after 0." | 3.66 | Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects. ( Angrist, B; Gershon, S; Rotrosen, J, 1980) |
| " Clinical evidence suggests that a similar agonist-induced hypersensitivity may play a role in the development of dyskinetic movement disorders and psychoses in humans following the chronic use of such dopamine agonists as amphetamine and levodopa." | 3.65 | Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders. ( Klawans, HL; Margolin, DI, 1975) |
| "If amphetamine can enhance the therapeutic effects of TCT, this would provide strong support for a "PACT" treatment paradigm for schizophrenia." | 2.84 | Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients. ( Alvarez, AI; Bhakta, SG; Hughes, EL; Light, GA; Rana, B; Swerdlow, NR; Talledo, J; Tarasenko, M; Vinogradov, S, 2017) |
| "Schizophrenia is a serious psychiatric disorder which impacts a broad range of cognitive, behavioural and emotional domains." | 2.44 | The amphetamine-induced sensitized state as a model of schizophrenia. ( Featherstone, RE; Fletcher, PJ; Kapur, S, 2007) |
| "gamma-Aminobutyric acid (GABA) is an important inhibitory neurotransmitter." | 2.36 | Biochemistry and the schizophrenia. Old concepts and new hypothesis. ( Berger, PA, 1981) |
| "Treatment with levetiracetam dose-dependently improved memory performance of the ketamine-exposed rats." | 1.48 | Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia. ( Gallagher, M; Koh, MT; Rosenzweig-Lipson, S; Shao, Y, 2018) |
| "The polyglutamine disease spinocerebellar ataxia type 17 (SCA17) is a neurodegenerative disease leading to severe neurological symptoms during development." | 1.46 | Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat. ( Amato, D; Bauer, P; Canneva, F; Müller, CP; Nguyen, HP; Riess, O; von Hörsten, S, 2017) |
| "PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure." | 1.42 | Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. ( Biawat, P; Cook, JM; Joksimović, S; Marković, B; Savić, MM; Stanković, T; Timić Stamenić, T, 2015) |
| " Mice treated with PGW5 (25 and 50mg/kg/d) for 28 days did not show toxic effects in terms of weight gain and blood-chemistry analysis." | 1.40 | A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia. ( Bidder, M; Gil-Ad, I; Kramer, M; Portnoy, M; Taler, M; Tarasenko, I; Weizman, A, 2014) |
| "Trials of novel compounds for the treatment of schizophrenia are typically tested in patients following brief withdrawal of ongoing medication despite known long-term changes in the dopamine (DA) system following chronic antipsychotic drug therapy." | 1.40 | Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. ( Cook, JM; Gill, KM; Grace, AA; Poe, MM, 2014) |
| "Schizophrenia is a disease typically associated with an adolescent onset." | 1.40 | An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia. ( Chen, L; Lodge, DJ; Perez, SM, 2014) |
| "Schizophrenia is believed to arise from an interaction of genetic predisposition and adverse environmental factors, with stress being a primary variable." | 1.39 | Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. ( Du, Y; Grace, AA, 2013) |
| "Haloperidol is an antipsychotic drug associated with the development of movement disorders." | 1.37 | Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. ( Barcelos, RC; Beck, RC; Benvegnú, DM; Boufleur, N; Bürger, ME; Ourique, AF; Pase, CS; Reckziegel, P, 2011) |
| " In addition, the side-effect profile was established by measuring catalepsy, antipsychotic-induced weight gain, plasma levels of prolactin, and anxiogenic potential." | 1.37 | AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. ( Arad, M; Barak, S; Black, MD; Borowsky, B; Cohen, C; De Levie, A; Featherstone, RE; Giardino, O; Griebel, G; Pichat, P; Rogacki, N; Senyah, Y; Stemmelin, J; Stevens, RJ; Varty, GB; Weiner, I, 2011) |
| " Chronic administration of clozapine (5 mg/kg s." | 1.36 | Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. ( Cilia, J; Dawson, LA; Gartlon, JE; Jones, DN; Moore, SH; Shilliam, C, 2010) |
| "Amphetamine pretreatment induced behavioral sensitization in both rat strains similarly." | 1.35 | The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms? ( Feldon, J; Hauser, J; Peleg-Raibstein, D; Yee, BK, 2009) |
| "Schizophrenia is a neuropsychiatric disorder of a neurodevelopmental origin manifested symptomatically after puberty." | 1.35 | Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia. ( Assaf, Y; Piontkewitz, Y; Weiner, I, 2009) |
| "Bipolar mania and schizophrenia are recognized as separate disorders but share many commonalities, which raises the question of whether they are the same disorder on different ends of a continuum." | 1.35 | A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. ( Ferguson, EJ; Geyer, MA; Henry, BL; Kincaid, MJ; Masten, VL; Minassian, A; Paulus, MP; Perry, W; Sharp, RF; Young, JW; Zhuang, X, 2009) |
| "The effects of paradoxical sleep deprivation (that worsens psychotic symptoms) and the performance in a latent inhibition protocol (an animal model of schizophrenia) were also verified." | 1.35 | Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia? ( Abílio, VC; Andersen, ML; Calzavara, MB; Frussa-Filho, R; Kameda, SR; Levin, R; Medrano, WA; Silva, RH; Tufik, S, 2009) |
| " In the present experiment, prefrontal acetylcholine (ACh) release was measured in attentional task-performing and non-performing rats pretreated with an escalating dosing regimen of amphetamine (AMPH) and following challenges with AMPH." | 1.34 | Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats. ( Brown, H; Bruno, JP; Kozak, R; Martinez, V; Sarter, M; Young, D, 2007) |
| "Using the rat Maximal Electroshock Seizure Threshold (MEST) test, (S)-3,4-DCPG (30 mg/kg, i." | 1.34 | Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia. ( Harris, AJ; Honey, A; Jones, DN; Jones, GA; Kelly, FM; Kew, JN; Maycox, PR; Melarange, RA; Murdock, PR; Robbins, MJ; Rocheville, M; Rourke, C; Rupniak, T; Soffin, EM; Starr, KR; Strum, J, 2007) |
| "Schizophrenia has been linked to dysregulation of dopamine and glutamate transmitter systems." | 1.33 | Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition. ( Fletcher, PJ; Kapur, S; Tenn, CC, 2005) |
| " This experiment assessed the consequences of the administration of an escalating dosing regimen of amphetamine (AMPH) on attentional performance." | 1.33 | Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats. ( Martinez, V; Parikh, V; Sarter, M, 2005) |
| "Animals were treated with continuous AMPH release (via osmotic mini-pumps at a dosage of 10 mg kg(-1) day(-1) for 7 days) and tested for their performance in L and PPI during withdrawal in a drug free state." | 1.33 | Withdrawal from continuous amphetamine administration abolishes latent inhibition but leaves prepulse inhibition intact. ( Feldon, J; Peleg-Raibstein, D; Russig, H; Sydekum, E, 2006) |
| "Catalepsy was induced by haloperidol (2 mg/kg p." | 1.33 | Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice. ( Akhtar, M; Ali, A; Pillai, KK; Uma Devi, P; Vohora, D, 2006) |
| "Schizophrenia is characterized by severe abnormalities in cognition, including disordered attention." | 1.32 | Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia. ( Grottick, AJ; Higgins, GA; Le Pen, G; Moreau, JL, 2003) |
| " The application schedule was validated, and the bioavailability of the compound determined, by means of a HPLC-pharmacokinetic study." | 1.32 | FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia. ( Boeckler, F; Feldon, J; Ferger, B; Gmeiner, P; Hübner, H; Löber, S; Russig, H; Schetz, J; Zhang, W, 2004) |
| "Schizophrenia is associated with increased birth complications, suggesting that birth complications might alter CNS dopaminergic activity later in life." | 1.31 | Birth insult alters dopamine-mediated behavior in a precocial species, the guinea pig. Implications for schizophrenia. ( Boksa, P; Vaillancourt, C, 2000) |
| "Rats treated with chlorpromazine (CPZ) (1 mg/kg/day i." | 1.27 | Amphetamine and chlorpromazine modify cerebral insulin levels in rats. ( Benedi, J; Cantón, R; Grande, C; Manzanares, J; Zaragozá, F, 1988) |
| "The diagnosis of schizophrenia is established principally by the presence of certain psychological symptoms which although subjective can be reliably assessed by standardized interviewing procedures." | 1.26 | Schizophrenia: the nature of the psychological disturbance and its possible neurochemcial basis. ( Crow, TJ, 1979) |
| " A long-term use of the preparation leads to development of habituation, while its cessation--to symptoms similar to withdrawal." | 1.26 | [Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)]. ( Bobritskaia, ZM; Gorbatko, LG; Litvinova, NM; Stoliarov, GV, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 130 (37.25) | 18.7374 |
| 1990's | 26 (7.45) | 18.2507 |
| 2000's | 78 (22.35) | 29.6817 |
| 2010's | 102 (29.23) | 24.3611 |
| 2020's | 13 (3.72) | 2.80 |
| Authors | Studies |
|---|---|
| Benvenutti, R | 1 |
| Gallas-Lopes, M | 1 |
| Sachett, A | 1 |
| Marcon, M | 1 |
| Strogulski, NR | 1 |
| Reis, CG | 1 |
| Chitolina, R | 1 |
| Piato, A | 1 |
| Herrmann, AP | 1 |
| Omeiza, NA | 1 |
| Bakre, AG | 1 |
| Abdulrahim, HA | 1 |
| Isibor, H | 1 |
| Ezurike, PU | 1 |
| Sowunmi, AA | 1 |
| Ben-Azu, B | 1 |
| Aderibigbe, AO | 1 |
| Lai, CC | 2 |
| Baskaran, R | 2 |
| Tsao, CY | 1 |
| Tuan, LH | 2 |
| Siow, PF | 1 |
| Palani, M | 1 |
| Lee, LJ | 4 |
| Liu, CM | 2 |
| Hwu, HG | 2 |
| Moya, NA | 3 |
| Yun, S | 3 |
| Fleps, SW | 3 |
| Martin, MM | 3 |
| Nadel, JA | 3 |
| Beutler, LR | 3 |
| Zweifel, LS | 3 |
| Parker, JG | 3 |
| Rafizadeh, R | 1 |
| Frankow, L | 1 |
| Mahmood, H | 1 |
| Poonia, S | 1 |
| Mathew, N | 1 |
| Danilewitz, M | 1 |
| Bousman, CA | 1 |
| Honer, WG | 1 |
| Schütz, CG | 1 |
| Swerdlow, NR | 5 |
| Bhakta, SG | 3 |
| Talledo, J | 2 |
| Benster, L | 1 |
| Kotz, J | 1 |
| Lavadia, M | 1 |
| Light, GA | 3 |
| Li, WY | 1 |
| Wang, CC | 1 |
| Nani, JV | 1 |
| Fonseca, MC | 1 |
| Engi, SA | 1 |
| Perillo, MG | 1 |
| Dias, CS | 1 |
| Gazarini, ML | 1 |
| Korth, C | 2 |
| Cruz, FC | 1 |
| Hayashi, MA | 1 |
| Young, JW | 2 |
| Roberts, BZ | 1 |
| Breier, M | 1 |
| You, MJ | 1 |
| Bang, M | 1 |
| Park, HS | 1 |
| Yang, B | 1 |
| Jang, KB | 1 |
| Yoo, J | 1 |
| Hwang, DY | 1 |
| Kim, M | 1 |
| Kim, B | 1 |
| Lee, SH | 1 |
| Kwon, MS | 1 |
| Issy, AC | 2 |
| Pedrazzi, JFC | 3 |
| van Oosten, ABS | 1 |
| Checheto, T | 1 |
| Silva, RR | 1 |
| Noël, F | 1 |
| Del-Bel, E | 2 |
| Zemba Cilic, A | 1 |
| Zemba, M | 1 |
| Cilic, M | 1 |
| Balenovic, I | 1 |
| Strbe, S | 1 |
| Ilic, S | 1 |
| Vukojevic, J | 1 |
| Zoricic, Z | 1 |
| Filipcic, I | 1 |
| Kokot, A | 1 |
| Drmic, D | 1 |
| Blagaic, AB | 1 |
| Tvrdeic, A | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Sales, AJ | 1 |
| Guimarães, FS | 2 |
| Joca, SRL | 1 |
| Crippa, JAS | 1 |
| Del Bel, E | 1 |
| Lange, HS | 1 |
| Vardigan, JD | 1 |
| Cannon, CE | 1 |
| Puri, V | 1 |
| Henze, DA | 1 |
| Uslaner, JM | 1 |
| Fletcher, PJ | 9 |
| Li, Z | 3 |
| Coen, KM | 1 |
| Lê, AD | 1 |
| Rajagopal, L | 1 |
| Kwon, S | 1 |
| Huang, M | 2 |
| Michael, E | 1 |
| Bhat, L | 1 |
| Cantillon, M | 1 |
| Meltzer, HY | 3 |
| Weinstein, JJ | 1 |
| van de Giessen, E | 3 |
| Rosengard, RJ | 1 |
| Xu, X | 3 |
| Ojeil, N | 2 |
| Brucato, G | 1 |
| Gil, RB | 1 |
| Kegeles, LS | 5 |
| Laruelle, M | 8 |
| Slifstein, M | 5 |
| Abi-Dargham, A | 10 |
| Koh, MT | 3 |
| Shao, Y | 2 |
| Rosenzweig-Lipson, S | 1 |
| Gallagher, M | 2 |
| Gill, KM | 3 |
| Miller, SA | 1 |
| Grace, AA | 7 |
| Talledo, JA | 1 |
| Franz, DM | 1 |
| Hughes, EL | 2 |
| Rana, BK | 1 |
| Nielsen, J | 1 |
| Fejgin, K | 1 |
| Sotty, F | 1 |
| Nielsen, V | 1 |
| Mørk, A | 3 |
| Christoffersen, CT | 1 |
| Yavich, L | 1 |
| Lauridsen, JB | 1 |
| Clausen, D | 1 |
| Larsen, PH | 2 |
| Egebjerg, J | 1 |
| Werge, TM | 1 |
| Kallunki, P | 1 |
| Christensen, KV | 1 |
| Didriksen, M | 3 |
| Frankle, WG | 1 |
| Paris, J | 1 |
| Himes, M | 1 |
| Mason, NS | 1 |
| Mathis, CA | 1 |
| Narendran, R | 3 |
| Klarer, M | 1 |
| Krieger, JP | 1 |
| Richetto, J | 2 |
| Weber-Stadlbauer, U | 1 |
| Günther, L | 1 |
| Winter, C | 2 |
| Arnold, M | 1 |
| Langhans, W | 1 |
| Meyer, U | 4 |
| Aguilar, DD | 1 |
| Giuffrida, A | 1 |
| Lodge, DJ | 9 |
| Nakao, K | 1 |
| Jeevakumar, V | 1 |
| Jiang, SZ | 1 |
| Fujita, Y | 1 |
| Diaz, NB | 1 |
| Pretell Annan, CA | 1 |
| Eskow Jaunarajs, KL | 1 |
| Hashimoto, K | 1 |
| Belforte, JE | 1 |
| Nakazawa, K | 1 |
| Mishra, A | 1 |
| Mishra, AK | 1 |
| Jha, S | 1 |
| Dos-Santos-Pereira, M | 1 |
| Kubrusly, RCC | 1 |
| Ahrens, PS | 1 |
| Voce, A | 1 |
| McKetin, R | 1 |
| Burns, R | 1 |
| Castle, D | 1 |
| Calabria, B | 1 |
| Cieślik, P | 1 |
| Woźniak, M | 2 |
| Rook, JM | 1 |
| Tantawy, MN | 1 |
| Conn, PJ | 1 |
| Acher, F | 2 |
| Tokarski, K | 2 |
| Kusek, M | 2 |
| Pilc, A | 3 |
| Wierońska, JM | 3 |
| Gray, A | 1 |
| Tattoli, R | 1 |
| Dunn, A | 1 |
| Hodgson, DM | 1 |
| Michie, PT | 1 |
| Harms, L | 1 |
| Uzuneser, TC | 1 |
| Schindehütte, M | 1 |
| Dere, E | 1 |
| von Hörsten, S | 2 |
| Kornhuber, J | 1 |
| Grömer, TW | 1 |
| Müller, CP | 2 |
| Grimm, CM | 1 |
| Aksamaz, S | 1 |
| Schulz, S | 1 |
| Teutsch, J | 1 |
| Sicinski, P | 1 |
| Liss, B | 1 |
| Kätzel, D | 1 |
| Mellsop, GW | 1 |
| Tapsell, R | 1 |
| Perez, SM | 5 |
| Donegan, JJ | 1 |
| Castellani, G | 1 |
| Contarini, G | 1 |
| Mereu, M | 2 |
| Albanesi, E | 1 |
| Devroye, C | 1 |
| D'Amore, C | 1 |
| Ferretti, V | 1 |
| De Martin, S | 1 |
| Papaleo, F | 4 |
| Du, Y | 1 |
| Willi, R | 2 |
| Harmeier, A | 1 |
| Giovanoli, S | 2 |
| Sławińska, A | 1 |
| Stachowicz, K | 1 |
| Marciniak, M | 2 |
| Lasoń-Tyburkiewicz, M | 2 |
| Gruca, P | 2 |
| Papp, M | 2 |
| Doller, D | 1 |
| Hawken, ER | 1 |
| Beninger, RJ | 1 |
| Ramshaw, H | 1 |
| Jaehne, EJ | 1 |
| McCarthy, P | 1 |
| Greenberg, Z | 1 |
| Saleh, E | 1 |
| McClure, B | 1 |
| Woodcock, J | 1 |
| Kabbara, S | 1 |
| Wiszniak, S | 1 |
| Wang, TY | 1 |
| Parish, C | 1 |
| van den Buuse, M | 4 |
| Baune, BT | 1 |
| Lopez, A | 1 |
| Schwarz, Q | 1 |
| Gil-Ad, I | 2 |
| Portnoy, M | 1 |
| Tarasenko, I | 1 |
| Bidder, M | 1 |
| Kramer, M | 1 |
| Taler, M | 1 |
| Weizman, A | 3 |
| Cook, JM | 3 |
| Poe, MM | 1 |
| Chen, L | 1 |
| Kilic, FS | 1 |
| Kulluk, D | 1 |
| Musmul, A | 1 |
| Gallo, A | 2 |
| Bouchard, C | 2 |
| Rompré, PP | 2 |
| Boley, AM | 1 |
| Fortier, E | 1 |
| Ducrot, C | 1 |
| Ingallinesi, M | 1 |
| Le Bouil, L | 1 |
| Biguet, NF | 1 |
| Thi, AD | 1 |
| Mannoury la Cour, C | 1 |
| Millan, MJ | 1 |
| Ravassard, P | 1 |
| Mallet, J | 1 |
| Meloni, R | 1 |
| Gevonden, M | 1 |
| Booij, J | 1 |
| van den Brink, W | 1 |
| Heijtel, D | 1 |
| van Os, J | 1 |
| Selten, JP | 1 |
| Su, P | 2 |
| Li, S | 1 |
| Chen, S | 1 |
| Lipina, TV | 2 |
| Wang, M | 2 |
| Lai, TK | 1 |
| Lee, FH | 1 |
| Zhang, H | 1 |
| Zhai, D | 1 |
| Ferguson, SS | 1 |
| Nobrega, JN | 1 |
| Wong, AH | 1 |
| Roder, JC | 2 |
| Liu, F | 3 |
| Gomes, FV | 1 |
| Van Snellenberg, J | 1 |
| Thompson, JL | 2 |
| Gil, R | 4 |
| Hackett, E | 1 |
| Girgis, R | 1 |
| Moore, H | 2 |
| D'Souza, D | 1 |
| Malison, RT | 1 |
| Huang, Y | 2 |
| Lim, K | 1 |
| Nabulsi, N | 1 |
| Carson, RE | 2 |
| Lieberman, JA | 2 |
| Rognli, EB | 3 |
| Medhus, SE | 1 |
| Bramness, JG | 3 |
| Lobmaier, PP | 1 |
| Larsen, GJ | 1 |
| Pitychoutis, PM | 1 |
| Belmer, A | 1 |
| Moutkine, I | 1 |
| Adrien, J | 1 |
| Maroteaux, L | 1 |
| Howe, WM | 1 |
| Tierney, PL | 1 |
| Young, DA | 1 |
| Oomen, C | 1 |
| Kozak, R | 2 |
| Chou, S | 1 |
| Jones, S | 1 |
| Li, M | 1 |
| Timić Stamenić, T | 1 |
| Joksimović, S | 2 |
| Biawat, P | 1 |
| Stanković, T | 2 |
| Marković, B | 1 |
| Savić, MM | 2 |
| Medhus, S | 2 |
| Gossop, M | 1 |
| Holm, B | 1 |
| Mørland, J | 1 |
| Choi, JK | 1 |
| Zhu, A | 1 |
| Jenkins, BG | 1 |
| Hattori, S | 1 |
| Kil, KE | 1 |
| Takagi, T | 1 |
| Ishii, S | 1 |
| Miyakawa, T | 2 |
| Brownell, AL | 1 |
| Batinić, B | 1 |
| Santrač, A | 1 |
| Divović, B | 1 |
| Timić, T | 1 |
| Obradović, ALj | 1 |
| Trossbach, SV | 1 |
| Bader, V | 1 |
| Hecher, L | 1 |
| Pum, ME | 1 |
| Masoud, ST | 1 |
| Prikulis, I | 1 |
| Schäble, S | 1 |
| de Souza Silva, MA | 1 |
| Boulat, B | 1 |
| Chwiesko, C | 1 |
| Poschmann, G | 1 |
| Stühler, K | 1 |
| Lohr, KM | 1 |
| Stout, KA | 1 |
| Oskamp, A | 1 |
| Godsave, SF | 1 |
| Müller-Schiffmann, A | 1 |
| Bilzer, T | 1 |
| Steiner, H | 1 |
| Peters, PJ | 1 |
| Bauer, A | 1 |
| Sauvage, M | 1 |
| Ramsey, AJ | 1 |
| Miller, GW | 1 |
| Seeman, P | 7 |
| Brandon, NJ | 1 |
| Huston, JP | 1 |
| Sherwood, A | 1 |
| Smith, DR | 1 |
| Engler, H | 1 |
| Engler, A | 1 |
| Feldon, J | 13 |
| Riva, MA | 1 |
| Schedlowski, M | 1 |
| Ceretta, APC | 1 |
| Schaffer, LF | 1 |
| de Freitas, CM | 1 |
| Reinheimer, JB | 1 |
| Dotto, MM | 1 |
| Fachinetto, R | 1 |
| Maia, TV | 1 |
| Frank, MJ | 1 |
| El-Sayed El-Sisi, A | 1 |
| Sokkar, SS | 1 |
| El-Sayed El-Sayad, M | 1 |
| Sayed Ramadan, E | 1 |
| Osman, EY | 1 |
| Managò, F | 1 |
| Mastwal, S | 1 |
| Mastrogiacomo, R | 1 |
| Scheggia, D | 1 |
| Emanuele, M | 1 |
| De Luca, MA | 1 |
| Weinberger, DR | 8 |
| Wang, KH | 1 |
| Tarasenko, M | 1 |
| Alvarez, AI | 1 |
| Rana, B | 1 |
| Vinogradov, S | 1 |
| Amato, D | 1 |
| Canneva, F | 1 |
| Nguyen, HP | 1 |
| Bauer, P | 1 |
| Riess, O | 1 |
| Black, MD | 2 |
| Varty, GB | 2 |
| Arad, M | 2 |
| Barak, S | 4 |
| De Levie, A | 2 |
| Boulay, D | 1 |
| Pichat, P | 2 |
| Griebel, G | 2 |
| Weiner, I | 9 |
| Mao, CV | 1 |
| Hori, E | 1 |
| Maior, RS | 1 |
| Maior, R | 1 |
| Ono, T | 1 |
| Nishijo, H | 1 |
| Geffen, Y | 1 |
| Nudelman, A | 1 |
| Rephaeli, A | 1 |
| Savitsky, K | 1 |
| Klapper, L | 1 |
| Winkler, I | 1 |
| Southam, E | 1 |
| Cilia, J | 2 |
| Gartlon, JE | 2 |
| Woolley, ML | 1 |
| Lacroix, LP | 1 |
| Jennings, CA | 1 |
| Cluderay, JE | 1 |
| Reavill, C | 1 |
| Rourke, C | 2 |
| Wilson, DM | 1 |
| Dawson, LA | 2 |
| Medhurst, AD | 1 |
| Jones, DN | 3 |
| Malkoff, A | 1 |
| Gozes, I | 1 |
| Rehavi, M | 2 |
| Errico, F | 1 |
| Rossi, S | 1 |
| Napolitano, F | 1 |
| Catuogno, V | 1 |
| Topo, E | 1 |
| Fisone, G | 1 |
| D'Aniello, A | 1 |
| Centonze, D | 1 |
| Usiello, A | 1 |
| Spoerri, E | 1 |
| Yee, BK | 5 |
| Schwarz, MJ | 1 |
| KIRMAN, BH | 1 |
| Ehrlichman, RS | 1 |
| Gandal, MJ | 1 |
| Maxwell, CR | 3 |
| Lazarewicz, MT | 1 |
| Finkel, LH | 1 |
| Contreras, D | 1 |
| Turetsky, BI | 1 |
| Siegel, SJ | 3 |
| Zmarowski, A | 1 |
| Wu, HQ | 1 |
| Brooks, JM | 2 |
| Potter, MC | 1 |
| Pellicciari, R | 1 |
| Schwarcz, R | 1 |
| Bruno, JP | 3 |
| Shilliam, C | 1 |
| Moore, SH | 1 |
| Peleg-Raibstein, D | 3 |
| Hauser, J | 1 |
| Bickel, S | 1 |
| Javitt, DC | 2 |
| Bertrand, JB | 1 |
| Langlois, JB | 1 |
| Bégou, M | 1 |
| Volle, J | 1 |
| Brun, P | 1 |
| d'Amato, T | 1 |
| Saoud, M | 1 |
| Suaud-Chagny, MF | 1 |
| Singer, P | 1 |
| Alexander, KS | 1 |
| Sarter, M | 3 |
| Piontkewitz, Y | 1 |
| Assaf, Y | 1 |
| Perry, W | 1 |
| Minassian, A | 1 |
| Paulus, MP | 1 |
| Kincaid, MJ | 1 |
| Ferguson, EJ | 1 |
| Henry, BL | 1 |
| Zhuang, X | 1 |
| Masten, VL | 1 |
| Sharp, RF | 1 |
| Geyer, MA | 2 |
| Kesby, JP | 1 |
| Cui, X | 1 |
| O'Loan, J | 1 |
| McGrath, JJ | 1 |
| Burne, TH | 1 |
| Eyles, DW | 1 |
| Weinmann, O | 1 |
| Klein, J | 1 |
| Sohr, R | 1 |
| Schnell, L | 1 |
| Schwab, ME | 1 |
| Liang, Y | 2 |
| Boules, M | 1 |
| Gordillo, A | 1 |
| Richelson, E | 1 |
| Niwa, M | 1 |
| Jaaro-Peled, H | 1 |
| Sawa, A | 2 |
| Pei, L | 1 |
| Kapur, S | 5 |
| Gururajan, A | 1 |
| Taylor, DA | 1 |
| Malone, DT | 1 |
| Perreault, ML | 1 |
| Hasbi, A | 1 |
| Alijaniaram, M | 1 |
| Fan, T | 1 |
| Varghese, G | 1 |
| O'Dowd, BF | 1 |
| George, SR | 1 |
| Fabricius, K | 1 |
| Steiniger-Brach, B | 1 |
| Helboe, L | 1 |
| Fink-Jensen, A | 1 |
| Wörtwein, G | 1 |
| Pietrzak, RH | 1 |
| Snyder, PJ | 1 |
| Maruff, P | 1 |
| Yang, F | 1 |
| Garcia, S | 1 |
| Chen, J | 1 |
| Lu, B | 1 |
| Crawley, JN | 1 |
| Basta-Kaim, A | 1 |
| Budziszewska, B | 1 |
| Leśkiewicz, M | 1 |
| Fijał, K | 2 |
| Regulska, M | 1 |
| Kubera, M | 1 |
| Wędzony, K | 2 |
| Lasoń, W | 1 |
| Enomoto, T | 1 |
| Tse, MT | 1 |
| Floresco, SB | 1 |
| Benvegnú, DM | 1 |
| Barcelos, RC | 1 |
| Boufleur, N | 1 |
| Reckziegel, P | 1 |
| Pase, CS | 1 |
| Ourique, AF | 1 |
| Beck, RC | 1 |
| Bürger, ME | 1 |
| Stevens, RJ | 1 |
| Rogacki, N | 1 |
| Featherstone, RE | 2 |
| Senyah, Y | 1 |
| Giardino, O | 1 |
| Borowsky, B | 2 |
| Stemmelin, J | 1 |
| Cohen, C | 1 |
| O'Daly, OG | 1 |
| Joyce, D | 1 |
| Stephan, KE | 1 |
| Murray, RM | 1 |
| Shergill, SS | 1 |
| Gravius, A | 1 |
| Laszy, J | 1 |
| Pietraszek, M | 1 |
| Sághy, K | 1 |
| Nagel, J | 1 |
| Chambon, C | 1 |
| Wegener, N | 1 |
| Valastro, B | 1 |
| Danysz, W | 1 |
| Gyertyán, I | 1 |
| Richtand, NM | 2 |
| Ahlbrand, R | 2 |
| Horn, P | 2 |
| Stanford, K | 1 |
| Bronson, SL | 2 |
| McNamara, RK | 2 |
| Jones, CA | 1 |
| Watson, DJ | 1 |
| Fone, KC | 1 |
| Naert, A | 1 |
| Callaerts-Vegh, Z | 1 |
| Moechars, D | 1 |
| Meert, T | 1 |
| D'Hooge, R | 1 |
| Aras, S | 1 |
| Levin, R | 2 |
| Calzavara, MB | 2 |
| Santos, CM | 1 |
| Medrano, WA | 2 |
| Niigaki, ST | 1 |
| Abílio, VC | 2 |
| Redrobe, JP | 1 |
| Elster, L | 1 |
| Frederiksen, K | 1 |
| Bundgaard, C | 1 |
| de Jong, IE | 1 |
| Smith, GP | 1 |
| Bruun, AT | 1 |
| van Gaalen, MM | 1 |
| Relo, AL | 1 |
| Mueller, BK | 1 |
| Gross, G | 1 |
| Mezler, M | 1 |
| Mahmood, D | 1 |
| Khanam, R | 1 |
| Pillai, KK | 2 |
| Akhtar, M | 2 |
| Tambyraja, R | 1 |
| Grainger, M | 1 |
| Schmidt-Hansen, M | 1 |
| Le Pelley, M | 1 |
| Beyaert, MG | 1 |
| Daya, RP | 1 |
| Dyck, BA | 1 |
| Johnson, RL | 1 |
| Mishra, RK | 1 |
| Law, AJ | 1 |
| Wang, Y | 1 |
| Sei, Y | 1 |
| O'Donnell, P | 1 |
| Piantadosi, P | 1 |
| Straub, RE | 1 |
| Huang, W | 1 |
| Thomas, CJ | 1 |
| Vakkalanka, R | 1 |
| Besterman, AD | 1 |
| Lipska, BK | 3 |
| Hyde, TM | 1 |
| Harrison, PJ | 1 |
| Kleinman, JE | 2 |
| Ma, TM | 1 |
| Abazyan, S | 1 |
| Abazyan, B | 1 |
| Nomura, J | 1 |
| Yang, C | 1 |
| Seshadri, S | 1 |
| Snyder, SH | 5 |
| Pletnikov, MV | 1 |
| Kömek, K | 1 |
| Bard Ermentrout, G | 1 |
| Walker, CP | 1 |
| Cho, RY | 1 |
| Cantrup, R | 1 |
| Sathanantham, K | 1 |
| Rushlow, WJ | 1 |
| Rajakumar, N | 1 |
| Urban, N | 1 |
| Girgis, RR | 1 |
| Beckerman, Y | 1 |
| Harkavy-Friedman, JM | 1 |
| Bédard, AM | 1 |
| Maheux, J | 1 |
| Lévesque, D | 1 |
| Samaha, AN | 1 |
| Shah, A | 2 |
| Asher, A | 1 |
| Gundersen, ØH | 1 |
| Guterstam, J | 1 |
| Konstenius, M | 1 |
| Løberg, EM | 1 |
| Tanum, L | 1 |
| Franck, J | 1 |
| Szekeres, G | 1 |
| Pávics, L | 1 |
| Janka, Z | 1 |
| Nishikawa, T | 1 |
| Ichikawa, J | 1 |
| Chung, YC | 1 |
| Dai, J | 2 |
| Le Pen, G | 1 |
| Grottick, AJ | 1 |
| Higgins, GA | 1 |
| Moreau, JL | 1 |
| Zuckerman, L | 2 |
| Rimmerman, N | 1 |
| Leiter, LM | 1 |
| Gerber, DJ | 2 |
| Gainetdinov, RR | 1 |
| Sotnikova, TD | 1 |
| Zeng, H | 1 |
| Caron, MG | 1 |
| Tonegawa, S | 2 |
| Nachman, R | 1 |
| Castner, SA | 2 |
| Goldman-Rakic, PS | 2 |
| Kusljic, S | 1 |
| Copolov, DL | 1 |
| COHEN, BD | 1 |
| SENF, R | 2 |
| HUSTON, PE | 2 |
| CALLIERI, B | 1 |
| RAVETTA, M | 1 |
| BROADHURST, A | 1 |
| TAKAHASHI, Y | 1 |
| AKABANE, Y | 1 |
| PROUT, CT | 1 |
| LYNN, GE | 1 |
| CLANCY, J | 1 |
| PFEIFFER, CC | 1 |
| GOLDSTEIN, L | 1 |
| MURPHREE, HB | 1 |
| SUGERMAN, AA | 1 |
| BELL, DS | 1 |
| Tenn, CC | 3 |
| Juárez, I | 1 |
| Silva-Gómez, AB | 1 |
| Peralta, F | 1 |
| Flores, G | 1 |
| HOPE, JM | 1 |
| CALLAWAY, E | 1 |
| SANDS, SL | 1 |
| ABELY, P | 1 |
| CHANEAC, H | 1 |
| VANECLOO, M | 1 |
| Boeckler, F | 1 |
| Russig, H | 3 |
| Zhang, W | 1 |
| Löber, S | 1 |
| Schetz, J | 1 |
| Hübner, H | 1 |
| Ferger, B | 1 |
| Gmeiner, P | 1 |
| McClure, WO | 1 |
| Ishtoyan, A | 1 |
| Lyon, M | 2 |
| Kipnis, J | 1 |
| Cohen, H | 1 |
| Cardon, M | 1 |
| Ziv, Y | 1 |
| Schwartz, M | 1 |
| Morris, M | 1 |
| Chavez, C | 1 |
| Martin, S | 1 |
| Wang, J | 1 |
| Flagstad, P | 1 |
| Glenthøj, BY | 1 |
| van Beek, J | 1 |
| Michael-Titus, AT | 1 |
| Williams, GV | 1 |
| Yui, K | 1 |
| Ikemoto, S | 1 |
| Sandner, G | 1 |
| Silva, RC | 1 |
| Angst, MJ | 1 |
| Knobloch, J | 1 |
| Danion, JM | 1 |
| Kanes, SJ | 2 |
| Abel, T | 2 |
| Howland, JG | 1 |
| Hannesson, DK | 1 |
| Phillips, AG | 1 |
| Koenig, JI | 1 |
| Elmer, GI | 1 |
| Shepard, PD | 1 |
| Lee, PR | 1 |
| Mayo, C | 1 |
| Joy, B | 1 |
| Hercher, E | 1 |
| Brady, DL | 1 |
| Härtel-Petri, R | 1 |
| Rodler, R | 1 |
| Schmeisser, U | 1 |
| Steinmann, J | 1 |
| Wolfersdorf, M | 1 |
| de Oliveira, RV | 1 |
| Dall'Igna, OP | 1 |
| Tort, AB | 1 |
| Schuh, JF | 1 |
| Neto, PF | 1 |
| Santos Gomes, MW | 1 |
| Souza, DO | 1 |
| Lara, DR | 1 |
| Jacobsen, JP | 1 |
| Rodriguiz, RM | 1 |
| Wetsel, WC | 1 |
| Martinez, V | 2 |
| Parikh, V | 1 |
| Chocyk, A | 1 |
| Barch, DM | 1 |
| Carter, CS | 1 |
| van Berckel, BN | 1 |
| Waterhouse, R | 1 |
| Guo, N | 1 |
| Hwang, DR | 1 |
| Van Heertum, R | 1 |
| Magdalan, J | 1 |
| Antończyk, A | 1 |
| Kochman, K | 1 |
| Porebska, B | 1 |
| Keist, R | 1 |
| von Boehmer, L | 1 |
| Studer, R | 1 |
| Benke, D | 1 |
| Hagenbuch, N | 1 |
| Dong, Y | 1 |
| Malenka, RC | 1 |
| Fritschy, JM | 1 |
| Bluethmann, H | 1 |
| Möhler, H | 1 |
| Rudolph, U | 1 |
| Sydekum, E | 1 |
| Jentsch, JD | 1 |
| Ghajarnia, M | 1 |
| Ko, F | 2 |
| Tallerico, T | 1 |
| Kelly, MP | 1 |
| Uma Devi, P | 1 |
| Ali, A | 1 |
| Vohora, D | 1 |
| Wolinsky, TD | 1 |
| Swanson, CJ | 1 |
| Smith, KE | 1 |
| Zhong, H | 1 |
| Branchek, T | 1 |
| Gerald, CP | 1 |
| Young, D | 1 |
| Brown, H | 1 |
| Suckling, CJ | 1 |
| Murphy, JA | 1 |
| Khalaf, AI | 1 |
| Zhou, SZ | 1 |
| Lizos, DE | 1 |
| van Nhien, AN | 1 |
| Yasumatsu, H | 1 |
| McVie, A | 1 |
| Young, LC | 1 |
| McCraw, C | 1 |
| Waterman, PG | 1 |
| Morris, BJ | 1 |
| Pratt, JA | 1 |
| Harvey, AL | 1 |
| Jack, E | 1 |
| Greenstein, R | 1 |
| Dean, B | 1 |
| Guillin, O | 1 |
| Robbins, MJ | 1 |
| Starr, KR | 1 |
| Honey, A | 1 |
| Soffin, EM | 1 |
| Jones, GA | 1 |
| Kelly, FM | 1 |
| Strum, J | 1 |
| Melarange, RA | 1 |
| Harris, AJ | 1 |
| Rocheville, M | 1 |
| Rupniak, T | 1 |
| Murdock, PR | 1 |
| Kew, JN | 1 |
| Maycox, PR | 1 |
| Kameda, SR | 1 |
| Andersen, ML | 1 |
| Tufik, S | 1 |
| Silva, RH | 1 |
| Frussa-Filho, R | 1 |
| Knuesel, I | 1 |
| Seelye, EE | 1 |
| Varga, E | 1 |
| Tringer, L | 1 |
| Smythies, JR | 1 |
| Johnston, VS | 2 |
| Bradley, RJ | 2 |
| Benington, F | 1 |
| Morin, RD | 1 |
| Clark, LC | 1 |
| Angrist, B | 7 |
| Rotrosen, J | 5 |
| Gershon, S | 7 |
| Toru, M | 1 |
| Luchins, DJ | 2 |
| Knight, JG | 1 |
| Mailman, RB | 1 |
| Lewis, MH | 1 |
| Kilts, CD | 1 |
| Saratikov, AS | 1 |
| Zamoshchina, TA | 1 |
| Alekseeva, LP | 1 |
| Agarkova, VP | 1 |
| Monroe, RR | 1 |
| Nielsen, EB | 1 |
| Eison, MS | 1 |
| Iversen, SD | 1 |
| Lubow, RE | 1 |
| Keitner, GI | 1 |
| Sabaawi, M | 1 |
| Haier, RJ | 1 |
| Kraemer, GW | 1 |
| Ebert, MH | 1 |
| Lake, CR | 1 |
| McKinney, WT | 2 |
| Moran, EC | 1 |
| Glick, SD | 1 |
| Weaver, LM | 1 |
| Meibach, RC | 1 |
| Wyatt, RJ | 1 |
| Potkin, SG | 1 |
| Jeste, DV | 1 |
| Berger, PA | 1 |
| Langer, DH | 1 |
| Brown, GL | 1 |
| Docherty, JP | 1 |
| Kokkinidis, L | 1 |
| Anisman, H | 1 |
| Corbett, R | 1 |
| Camacho, F | 1 |
| Woods, AT | 1 |
| Kerman, LL | 1 |
| Fishkin, RJ | 1 |
| Brooks, K | 1 |
| Dunn, RW | 1 |
| Janssen, PA | 1 |
| Awouters, FH | 1 |
| Stevens, KE | 1 |
| Meltzer, J | 1 |
| Rose, GM | 1 |
| Glenthøj, B | 1 |
| Mogensen, J | 1 |
| Laursen, H | 1 |
| Holm, S | 1 |
| Hemmingsen, R | 1 |
| Rückert, NG | 1 |
| Schmidt, WJ | 1 |
| Flaum, M | 1 |
| Schultz, SK | 1 |
| Sanfilipo, M | 1 |
| Wolkin, A | 3 |
| van Kammen, DP | 2 |
| Duncan, E | 1 |
| Wieland, S | 1 |
| Cooper, TB | 2 |
| Peselow, ED | 1 |
| van Dyck, CH | 3 |
| D'Souza, CD | 1 |
| Erdos, J | 1 |
| McCance, E | 1 |
| Rosenblatt, W | 1 |
| Fingado, C | 1 |
| Zoghbi, SS | 1 |
| Baldwin, RM | 2 |
| Seibyl, JP | 2 |
| Krystal, JH | 1 |
| Charney, DS | 2 |
| Innis, RB | 3 |
| Chambers, RA | 1 |
| Moore, J | 1 |
| McEvoy, JP | 1 |
| Levin, ED | 1 |
| Tibbo, P | 1 |
| Silverstone, PH | 1 |
| McEwan, AJ | 1 |
| Scott, J | 1 |
| Joshua, A | 1 |
| Golberg, K | 1 |
| Lysaker, PH | 1 |
| Bell, MD | 1 |
| Bioty, SM | 1 |
| Zito, WS | 1 |
| King, D | 1 |
| Zigmond, MJ | 1 |
| Finlay, JM | 1 |
| Breier, A | 2 |
| Su, TP | 1 |
| Saunders, R | 1 |
| Kolachana, BS | 1 |
| de Bartolomeis, A | 1 |
| Weisenfeld, N | 1 |
| Malhotra, AK | 1 |
| Eckelman, WC | 1 |
| Pickar, D | 2 |
| Pierce, RC | 1 |
| Kalivas, PW | 1 |
| Krystal, J | 1 |
| Bowers, M | 1 |
| Feifel, D | 1 |
| Reza, T | 1 |
| Shaner, A | 1 |
| Taylor, G | 1 |
| Bardgett, M | 1 |
| Csernansky, J | 1 |
| Early, T | 1 |
| Haller, J | 1 |
| Scherrer, J | 1 |
| Womack, S | 1 |
| Dursun, SM | 1 |
| Wright, N | 1 |
| Reveley, MA | 1 |
| Broersen, LM | 1 |
| Bertolino, A | 1 |
| Callicott, JH | 1 |
| Adler, C | 1 |
| Mattay, VS | 1 |
| Shapiro, M | 1 |
| Frank, JA | 1 |
| Lacroix, L | 1 |
| Spinelli, S | 1 |
| White, W | 1 |
| Zea-Ponce, Y | 1 |
| Rodenhiser-Hill, J | 1 |
| Mann, JJ | 1 |
| Van Heertum, RL | 1 |
| Carlsson, A | 1 |
| Vaillancourt, C | 1 |
| Boksa, P | 1 |
| Martinez, D | 1 |
| Gelernter, J | 1 |
| Kegeles, L | 1 |
| Guan, HJ | 1 |
| Zhu, XZ | 1 |
| Ellenbroek, BA | 1 |
| Liégeois, JF | 1 |
| Bruhwyler, J | 1 |
| Cools, AR | 1 |
| Balla, A | 1 |
| Koneru, R | 1 |
| Smiley, J | 1 |
| Sershen, H | 1 |
| Halim, N | 1 |
| Hanlon, FM | 1 |
| Platten, A | 1 |
| Auerbach, PP | 1 |
| Murphy, CA | 1 |
| Fend, M | 1 |
| Ito, C | 1 |
| Halim, ND | 1 |
| Segal, PN | 1 |
| Hornykiewicz, O | 2 |
| Crow, TJ | 3 |
| Sever, PS | 1 |
| Lamprecht, F | 1 |
| Sachar, EJ | 1 |
| Traficante, LJ | 1 |
| Hine, B | 1 |
| Sakalis, G | 1 |
| Bobritskaia, ZM | 1 |
| Gorbatko, LG | 1 |
| Litvinova, NM | 1 |
| Stoliarov, GV | 2 |
| Munkvad, I | 3 |
| McLellan, AT | 1 |
| Druley, KA | 1 |
| Barry, VC | 1 |
| Klawans, HL | 3 |
| Crayton, JW | 1 |
| Smith, RC | 1 |
| Klass, D | 1 |
| Chang, S | 1 |
| Ericksen, SE | 1 |
| Saletu, B | 1 |
| Brook, R | 2 |
| Szandorowska, B | 1 |
| Whitehead, PC | 2 |
| Langer, G | 1 |
| Heinze, G | 1 |
| Reim, B | 1 |
| Matussek, N | 1 |
| Kakimoto, Y | 1 |
| Wray, SR | 1 |
| Margolin, DI | 1 |
| Siomopoulos, V | 1 |
| Bergen, JR | 1 |
| Mulhall, S | 1 |
| Moorman, P | 1 |
| Devis, D | 1 |
| Luchins, D | 1 |
| Utena, H | 1 |
| Niwa, S | 1 |
| Kato, A | 1 |
| Tsuji, M | 1 |
| Nakamura, M | 1 |
| Nakajima, T | 1 |
| Kinon, BJ | 1 |
| Loebel, AD | 1 |
| Connell, P | 1 |
| Mueser, KT | 1 |
| Yarnold, PR | 1 |
| Levinson, DF | 1 |
| Singh, H | 1 |
| Bellack, AS | 1 |
| Kee, K | 1 |
| Morrison, RL | 1 |
| Yadalam, KG | 1 |
| Peselow, E | 1 |
| Rubinstein, M | 1 |
| Cesarec, Z | 2 |
| Nyman, AK | 1 |
| Baruch, I | 1 |
| Hemsley, DR | 1 |
| Gray, JA | 1 |
| Wolf, A | 1 |
| Brodie, J | 1 |
| Wolkin, B | 1 |
| Jaeger, J | 1 |
| Cancro, R | 1 |
| Manzanares, J | 1 |
| Cantón, R | 1 |
| Grande, C | 1 |
| Benedi, J | 1 |
| Zaragozá, F | 1 |
| Rosen, J | 1 |
| Peters, J | 1 |
| Fields, R | 1 |
| van Kammen, WB | 1 |
| Laplante, M | 1 |
| St-Laurent, J | 1 |
| Schmidt, CW | 1 |
| Lipton, MA | 1 |
| Greenblatt, DJ | 1 |
| Shader, RI | 1 |
| Matthysse, S | 3 |
| Kety, SS | 1 |
| Kaplun, J | 1 |
| Randrup, A | 1 |
| Goetz, C | 1 |
| Westheimer, R | 1 |
| Lynn, EJ | 1 |
| Schnee, J | 1 |
| Bilikiewicz, A | 1 |
| Góra, S | 1 |
| Johnson, G | 1 |
| Janowski, DS | 1 |
| Davis, JM | 2 |
| El-Yousef, MK | 1 |
| Breakey, WR | 1 |
| Goodell, H | 1 |
| Lorenz, PC | 1 |
| McHugh, PR | 1 |
| Sathananthan, G | 1 |
| Wilk, S | 1 |
| Gillbe, C | 2 |
| Os'makova, EI | 1 |
| Enelow, AJ | 1 |
| Stone, MH | 1 |
| Wender, PH | 1 |
| Eberhard, G | 1 |
| Nordgren, L | 1 |
| Aggernaes, A | 1 |
| Glick, ID | 1 |
| Winstead, DK | 1 |
| Labhardt, F | 1 |
| Wyss, P | 1 |
| West, AP | 1 |
| Green, RS | 1 |
| Rau, JH | 1 |
| Kuhn, R | 1 |
| Taeschler, M | 1 |
| Schoch, J | 1 |
| Faurbye, A | 2 |
| Price, J | 1 |
| Hopkinson, G | 1 |
| Winslow, WW | 2 |
| Stone, WN | 2 |
| Hofling, CK | 2 |
| Cole, JO | 1 |
| Brodsky, L | 1 |
| Mashkovskiĭ, MD | 2 |
| Park, LC | 1 |
| Imboden, JB | 1 |
| Tucker, GJ | 1 |
| Quinlan, D | 1 |
| Harrow, M | 1 |
| de Groot, MH | 1 |
| Bardwell, B | 1 |
| Wikler, A | 1 |
| Haertzen, CA | 1 |
| Chessick, RD | 1 |
| Hill, HE | 1 |
| Pescor, FT | 1 |
| Matveĭchuk, TS | 1 |
| Polezhaeva, AI | 1 |
| Avrutskii, GIa | 1 |
| Vertozgadova, OP | 1 |
| Smulevich, AB | 1 |
| Cohen, M | 1 |
| Klein, DF | 1 |
| Arushanian, EB | 1 |
| Tolpyshev, BA | 1 |
| Poliakov, VD | 1 |
| Gilmour, DG | 1 |
| Bloom, AD | 1 |
| Lele, KP | 1 |
| Robbins, ES | 1 |
| Maximilian, C | 1 |
| Lehmann, HE | 1 |
| Ban, TA | 1 |
| Kral, VA | 1 |
| Rockwell, DA | 2 |
| Ostwald, P | 1 |
| Proctor, CD | 1 |
| Cho, JB | 1 |
| Potts, JL | 1 |
| Ashley, LG | 1 |
| Douglas, JG | 1 |
| Amoroso, CP | 1 |
| McGriff, JE | 1 |
| Eaton, HE | 1 |
| Hekimian, LJ | 1 |
| Eggert Hansen, C | 1 |
| Milman, DH | 1 |
| Johnson, J | 1 |
| Milner, G | 1 |
| Merini, A | 1 |
| D'Urso, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Examining the Effects of Estradiol on Neural and Molecular Response to Rewards in Perimenopausal-Onset Anhedonia and Psychosis[NCT05282277] | Phase 4 | 103 participants (Anticipated) | Interventional | 2022-04-20 | Recruiting | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Dysbindin-antipsychotics Psychophamarcogenetics: a Mouse-human Translational Study Towards Personalized Healthcare in Bipolar Disorders[NCT06167577] | 150 participants (Actual) | Observational | 2018-11-08 | Completed | |||
| The Impact of Caffeine on Cognition in Schizophrenia[NCT02832401] | 24 participants (Actual) | Interventional | 2016-09-02 | Completed | |||
| Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia[NCT03323437] | Phase 4 | 47 participants (Actual) | Interventional | 2017-09-15 | Completed | ||
| PET Assays of Striatal Dopamine Markers in Cocaine Craving[NCT01036516] | 14 participants (Anticipated) | Observational | 1998-06-23 | Completed | |||
| Brain Circuits in Schizophrenia and Smoking[NCT01369966] | 42 participants (Actual) | Observational | 2011-05-16 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
47 reviews available for amphetamine and Dementia Praecox
| Article | Year |
|---|---|
An Integrative Perspective on the Role of Dopamine in Schizophrenia.
Topics: Amphetamine; Animals; Brain; Corpus Striatum; Dopamine; Dopaminergic Neurons; Humans; Models, Neurol | 2017 |
Current pharmacological models of social withdrawal in rats: relevance to schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cannabinoids; Disease Models, Animal; Excitatory Amino A | 2010 |
Animal models of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition Disorders; Disease Models, Animal; Female; Hum | 2011 |
The positive symptoms of acute schizophrenia and latent inhibition in humans and animals: underpinned by the same process(es)?
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease M | 2012 |
Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?
Topics: Amphetamine; Diagnosis, Differential; Disease Susceptibility; Humans; Methamphetamine; Models, Psych | 2012 |
[Investigation of the dopamine dysregulation hypothesis of schizophrenia with neuroimaging techniques].
Topics: Amphetamine; Dopamine; Dopamine Agents; Excitatory Amino Acid Agonists; Humans; Magnetic Resonance I | 2002 |
[Genetic study on schizophrenia and its recurrence utilizing pharmacological models].
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cocaine; Disease Models, Animal; Dopamine A | 2002 |
Animal models of working memory: insights for targeting cognitive dysfunction in schizophrenia.
Topics: Amphetamine; Animals; Cognition Disorders; Dopamine; Glutamic Acid; Humans; Memory, Short-Term; Mode | 2004 |
[Stress sensitization induced by stressor and methamphetamine].
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Central Nervous System Stimulants; Disease Models, An | 2004 |
Neurobiology of dopamine in schizophrenia.
Topics: Amphetamine; Animals; Brain; Cognition Disorders; Corpus Striatum; Dopamine; Dopamine Plasma Membran | 2007 |
The amphetamine-induced sensitized state as a model of schizophrenia.
Topics: Amphetamine; Animals; Brain; Brain Chemistry; Central Nervous System Stimulants; Cognition Disorders | 2007 |
[Biologically active amines and schizophrenia (author's transl)].
Topics: Amphetamine; Animals; Biogenic Amines; Brain; Humans; Rats; Schizophrenia; Substance-Related Disorde | 1981 |
Animal models related to developmental disorders: theoretical and pharmacological analyses.
Topics: 5,7-Dihydroxytryptamine; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Brain; | 1981 |
The schizophrenia syndrome. Examples of biological tools for subclassification.
Topics: Amphetamine; Blood Platelets; Dominance, Cerebral; Dyskinesia, Drug-Induced; Functional Laterality; | 1981 |
Biochemistry and the schizophrenia. Old concepts and new hypothesis.
Topics: Acetylcholine; Amphetamine; Animals; Brain; Cocaine; Dopamine; Endorphins; gamma-Aminobutyric Acid; | 1981 |
Dopamine receptor supersensitivity and schizophrenia: a review.
Topics: Adenylyl Cyclases; Amphetamine; Animals; Apomorphine; Brain Chemistry; Dopamine; Female; Guinea Pigs | 1981 |
Amphetamine psychosis and schizophrenia: a dual model.
Topics: Amphetamine; Animals; Disease Models, Animal; Dopamine; Humans; Norepinephrine; Psychoses, Substance | 1981 |
A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Humans; Models, Neurological; Neurons; Nucl | 1997 |
Commentary on: "Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia." Psychopharmacology (1980) 72:17-19.
Topics: Amphetamine; Antipsychotic Agents; Dopamine Uptake Inhibitors; Humans; Schizophrenia; Schizophrenic | 2001 |
Analysis of overall gene expression induced by amphetamine and phencyclidine: novel targets for the treatment of drug psychosis and schizophrenia.
Topics: Amphetamine; Animals; Dopamine Agents; Gene Expression Regulation; Hallucinogens; Humans; Phencyclid | 2002 |
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Brain Chemistry; Cats; Corp | 1977 |
Psychopharmacological implications of dopamine and dopamine antagonists: a critical evaluation of current evidence.
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Behavior; Brain; Corpus Str | 1978 |
Epilepsy and schizophrenia: a neurochemical bridge.
Topics: Amphetamine; Anticonvulsants; Brain; Butyrophenones; Disulfiram; Dopamine; Dopamine beta-Hydroxylase | 1977 |
Evidence for neuroendocrine abnormalities in the major mental illnesses.
Topics: Adrenocorticotropic Hormone; Aged; Amphetamine; Bipolar Disorder; Chlorpromazine; Circadian Rhythm; | 1975 |
On the role of dopamine in the pathophysiology of anorexia nervosa.
Topics: 17-Ketosteroids; Amphetamine; Anorexia Nervosa; Apomorphine; Compulsive Personality Disorder; Dopami | 1976 |
Biological psychiatry: on the relationship of schizophrenia and dopaminergic hyperactivity.
Topics: Amphetamine; Animals; Chlorpromazine; Corpus Striatum; Dopamine; Environment; Hallucinogens; Haloper | 1975 |
Dopaminergic mechanisms in idiopathic and drug-induced psychoses.
Topics: Amphetamine; Animals; Brain; Cocaine; Dopamine; Dose-Response Relationship, Drug; Humans; Psychoses, | 1990 |
[Research into the biochemical bases of schizophrenic syndromes: a review].
Topics: Alpha-Globulins; Amphetamine; Ceruloplasmin; Energy Metabolism; Fenclonine; gamma-Globulins; Halluci | 1973 |
Drug therapy reviews: rational use of psychotropic drugs. III. Major tranquilizers.
Topics: Adrenergic alpha-Agonists; Adult; Alcoholism; Amphetamine; Antiemetics; Antipsychotic Agents; Body T | 1974 |
Implications of catecholamine systems of the brain in schizophrenia.
Topics: Amphetamine; Brain; Catecholamines; Chlorpromazine; Dihydroxyphenylalanine; Dopamine; Histamine H1 A | 1974 |
Pharmacology and physiology of stereotyped behavior.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior; Behavior, Animal; Bipolar Disorder; | 1974 |
Pathophysiology of schizophrenia and the striatum.
Topics: Adult; Amphetamine; Animals; Basal Ganglia; Catalepsy; Caudate Nucleus; Dihydroxyphenylalanine; Dopa | 1972 |
Catecholamines in the brain as mediators of amphetamine psychosis.
Topics: Amphetamine; Animals; Antidepressive Agents; Brain Chemistry; Bromides; Catecholamines; Cats; Cocain | 1972 |
Differential response to psychotropic drugs.
Topics: Adult; Affective Symptoms; Amphetamine; Antidepressive Agents; Bipolar Disorder; Central Nervous Sys | 1971 |
The use and abuse of the psychotropic drugs.
Topics: Adult; Amphetamine; Antidepressive Agents; Anxiety; Chlorpromazine; Depression; Drug Utilization; Fe | 1973 |
Drug-related schizophrenic syndromes.
Topics: Amphetamine; Bipolar Disorder; Cannabis; Diagnosis, Differential; Female; Humans; Lysergic Acid Diet | 1973 |
Some speculations concerning a possible biochemical basis of minimal brain dysfunction.
Topics: Acute Disease; Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Behavior; Behavi | 1974 |
Molecular pharmacology of hallucinogens.
Topics: Amphetamine; Animals; Avoidance Learning; Brain; Conditioning, Operant; Emotions; Hallucinogens; Hum | 1968 |
The role of amines in the etiology of schizophrenia.
Topics: Adrenochrome; Amines; Amphetamine; Brain Chemistry; Dopamine; Epinephrine; Humans; Indoles; Kynureni | 1968 |
Mono-amine oxidase inhibitors and schizophrenia.
Topics: Acute Disease; Amines; Amphetamine; Chronic Disease; Hallucinogens; Humans; Iproniazid; Isoniazid; M | 1968 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Psychopharmacology and psychopathology.
Topics: Amphetamine; Barbiturates; Catatonia; Depression; Humans; Mental Disorders; Neurotic Disorders; Para | 1969 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Butyrophenones; Electroencephalography; Humans; Hypnotics and Se | 1969 |
A biochemical survey of schizophrenia.
Topics: Amines; Amphetamine; Antibodies; Antigen-Antibody Reactions; Antimetabolites; Biotransformation; Blo | 1970 |
[Adrenergic mechanisms of antidepressant action].
Topics: Amphetamine; Animals; Antidepressive Agents; Brain; Brain Chemistry; Cats; Depression; Dogs; Humans; | 1970 |
Clinical and heuristic value of clinical drug research.
Topics: Affective Symptoms; Amitriptyline; Amphetamine; Butyrophenones; Child Behavior Disorders; Chlorproma | 1970 |
Biogenic amines and psychiatry.
Topics: 5-Hydroxytryptophan; Affective Symptoms; Amines; Amphetamine; Anxiety Disorders; Attention Deficit D | 1971 |
19 trials available for amphetamine and Dementia Praecox
| Article | Year |
|---|---|
Increased release of dopamine in the striata of young adults with hearing impairment and its relevance for the social defeat hypothesis of schizophrenia.
Topics: Adult; Amphetamine; Blood Pressure; Central Nervous System Sensitization; Corpus Striatum; Dopamine; | 2014 |
Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients.
Topics: Adult; Amphetamine; Auditory Perception; Central Nervous System Stimulants; Cognitive Dysfunction; C | 2017 |
Amphetamine-related improvement in executive function in patients with chronic schizophrenia is modulated by practice effects.
Topics: Adult; Amphetamine; Chronic Disease; Cognition; Diagnostic and Statistical Manual of Mental Disorder | 2010 |
Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers.
Topics: Adult; Amphetamine; Brain; Caudate Nucleus; Cognition; Dopamine Uptake Inhibitors; Double-Blind Meth | 2011 |
Dopamine and gamma band synchrony in schizophrenia--insights from computational and empirical studies.
Topics: Adolescent; Adult; Amphetamine; Brain Waves; Computer Simulation; Cortical Synchronization; Dopamine | 2012 |
Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers.
Topics: Adult; Amphetamine; Analysis of Variance; Antipsychotic Agents; Central Nervous System Stimulants; C | 2005 |
Amphetamine and negative symptoms of schizophrenia.
Topics: Adult; Amphetamine; Analysis of Variance; Follow-Up Studies; Humans; Male; Middle Aged; Psychiatric | 1996 |
Effects of amphetamine on saccadic eye movements in man: possible relevance to schizophrenia?
Topics: Adult; Amphetamine; Central Nervous System Stimulants; Female; Humans; Male; Prospective Studies; Ps | 1999 |
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.
Topics: Adult; Amphetamine; Benzamides; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Antagonists; Ex | 2000 |
Chloroquine potentiation of thioridazine effects in rats and drug-resistant schizophrenic patients: a preliminary report.
Topics: Amphetamine; Animals; Brain; Chloroquine; Clinical Trials as Topic; Drug Resistance; Drug Synergism; | 1977 |
Differential performance of acute and chronic schizophrenics in a latent inhibition task.
Topics: Adult; Amphetamine; Antipsychotic Agents; Association Learning; Attention; Conditioning, Classical; | 1988 |
Effects of amphetamine on local cerebral metabolism in normal and schizophrenic subjects as determined by positron emission tomography.
Topics: Adult; Amphetamine; Brain; Brain Chemistry; Chronic Disease; Humans; Kinetics; Male; Middle Aged; Sc | 1987 |
[Use of psychological methods for studying the particular psychotropic action of various psychopharmacologic drugs].
Topics: Adult; Amphetamine; Association; Attention; Chlorpromazine; Clinical Trials as Topic; Eye Movements; | 1972 |
A controlled study of the antipsychotic and sedative effects of neuroleptic drugs and amphetamine in chronic schizophrenics. A clinical and experimental-psychological study.
Topics: Adult; Amphetamine; Chronic Disease; Clinical Trials as Topic; Delayed-Action Preparations; Depressi | 1974 |
[Pharmacologic and clinical properties of a new butyrophenone derivative (FR 33)].
Topics: Adult; Amphetamine; Animals; Antidepressive Agents; Butyrophenones; Catalepsy; Catatonia; Clinical T | 1966 |
Drug therapy.
Topics: Amphetamine; Antidepressive Agents; Chlorpromazine; Chlorprothixene; Clinical Trials as Topic; Hallu | 1967 |
Clinical and heuristic value of clinical drug research.
Topics: Affective Symptoms; Amitriptyline; Amphetamine; Butyrophenones; Child Behavior Disorders; Chlorproma | 1970 |
Reaction time ("mental set") in control and chronic schizophrenic subjects and in postaddicts under placebo, LSD-25, morphine, pentobarbital and amphetamine.
Topics: Adult; Amphetamine; Clinical Trials as Topic; Female; Humans; Lysergic Acid Diethylamide; Male; Midd | 1965 |
Psychological tests: practice effect in geriatric patients.
Topics: Aged; Amobarbital; Amphetamine; Carbon Dioxide; Female; Humans; Male; Mental Disorders; Middle Aged; | 1968 |
285 other studies available for amphetamine and Dementia Praecox
| Article | Year |
|---|---|
How do zebrafish (Danio rerio) respond to MK-801 and amphetamine? Relevance for assessing schizophrenia-related endophenotypes in alternative model organisms.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Endophenotypes; Female; Male; Mice; Rats; Receptors, N-Me | 2021 |
Pretreatment with Carpolobia lutea ethanol extract prevents schizophrenia-like behavior in mice models of psychosis.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Ethanol; Ketamine; Male; Mice; Plant Extrac | 2022 |
Chronic N-Acetylcysteine Treatment Prevents Amphetamine-Induced Hyperactivity in Heterozygous
Topics: Acetylcysteine; Amphetamine; Animals; Disease Models, Animal; Dopamine; Female; Glycogen Synthase Ki | 2022 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
The effect of selective nigrostriatal dopamine excess on behaviors linked to the cognitive and negative symptoms of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cognition; Dopamine; Dopaminergic Neurons; Haloperidol; | 2023 |
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study.
Topics: Amphetamine; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; Female; Humans; Mal | 2023 |
Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients.
Topics: Adult; Amphetamine; Antipsychotic Agents; Blood Pressure; Dopamine Agents; Female; Heart Rate; Human | 2019 |
Characterization of striatal phenotypes in heterozygous Disc1 mutant mice, a model of haploinsufficiency.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Corpus Striatum; Disease | 2020 |
Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity.
Topics: Amphetamine; Animals; Animals, Genetically Modified; Brain; Cell Count; Cell Nucleus; Central Nervou | 2020 |
Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment.
Topics: Amphetamine; Animals; Attention; Central Nervous System Stimulants; Choice Behavior; Dopamine Antago | 2020 |
Human umbilical cord-derived mesenchymal stem cells alleviate schizophrenia-relevant behaviors in amphetamine-sensitized mice by inhibiting neuroinflammation.
Topics: Amphetamine; Animals; Genome-Wide Association Study; Humans; Mesenchymal Stem Cell Transplantation; | 2020 |
Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Anti-Bacterial Age | 2020 |
Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy. BPC 157, L-NAME, L-arginine, NO-relation, in the suited rat acute and chronic models resembling 'positive-like' symptoms of schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Arginine; Behavior, Animal; Catalepsy; Disease Models, Animal; Di | 2021 |
Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Cannabidiol; Clozapine; Dizocilpine Ma | 2021 |
Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey.
Topics: Alzheimer Disease; Amphetamine; Animals; Association Learning; Behavior, Animal; Central Nervous Sys | 2021 |
Acquisition of nicotine self-administration in amphetamine and phencyclidine models of schizophrenia: A role for stress?
Topics: Amphetamine; Animals; Disease Models, Animal; Learning; Male; Motor Activity; Nicotine; Nicotinic Ag | 2018 |
RP5063, an atypical antipsychotic drug with a unique pharmacologic profile, improves declarative memory and psychosis in mouse models of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Cerebral Cortex; Cond | 2017 |
PET imaging of dopamine-D2 receptor internalization in schizophrenia.
Topics: Adult; Amphetamine; Carbon Radioisotopes; Case-Control Studies; Central Nervous System Stimulants; D | 2018 |
Treatment with levetiracetam improves cognition in a ketamine rat model of schizophrenia.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Disease Models, Animal | 2018 |
Impaired contextual fear-conditioning in MAM rodent model of schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Central Nervous System Stimulants; Conditioning, Classical; | 2018 |
Effects of Amphetamine on Sensorimotor Gating and Neurocognition in Antipsychotic-Medicated Schizophrenia Patients.
Topics: Adolescent; Adult; Amphetamine; Antipsychotic Agents; Cognition; Female; Humans; Male; Mental Status | 2018 |
A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission.
Topics: Abnormalities, Multiple; Amphetamine; Animals; Apomorphine; Behavior, Animal; Benzazepines; Chromoso | 2017 |
Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.
Topics: Adolescent; Adult; Amphetamine; Apomorphine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine | 2018 |
Abdominal Vagal Afferents Modulate the Brain Transcriptome and Behaviors Relevant to Schizophrenia.
Topics: Abdomen; Amphetamine; Animals; Association Learning; Attention; Brain Chemistry; Denervation; Dopami | 2018 |
Adolescent Synthetic Cannabinoid Exposure Produces Enduring Changes in Dopamine Neuron Activity in a Rodent Model of Schizophrenia Susceptibility.
Topics: Age Factors; Amphetamine; Animals; Behavior, Animal; Cannabinoids; Central Nervous System Stimulants | 2018 |
Schizophrenia-Like Dopamine Release Abnormalities in a Mouse Model of NMDA Receptor Hypofunction.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Disease Models, Animal; D | 2019 |
Effect of traditional medicine brahmi vati and bacoside A-rich fraction of Bacopa monnieri on acute pentylenetetrzole-induced seizures, amphetamine-induced model of schizophrenia, and scopolamine-induced memory loss in laboratory animals.
Topics: Acetylcholinesterase; Amnesia; Amphetamine; Animals; Animals, Laboratory; Antioxidants; Bacopa; Brai | 2018 |
The role of striatum and prefrontal cortex in the prevention of amphetamine-induced schizophrenia-like effects mediated by nitric oxide compounds.
Topics: Amphetamine; Animals; Antipsychotic Agents; Corpus Striatum; Cyclic AMP; Dizocilpine Maleate; Male; | 2018 |
Is it Pre- or Postsynaptic? Imaging Striatal Dopamine Excess in Schizophrenia.
Topics: Amphetamine; Corpus Striatum; Dopamine; Humans; Schizophrenia | 2018 |
A greater tendency for representation mediated learning in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Delusions; Disease Mo | 2018 |
The relationship between illicit amphetamine use and psychiatric symptom profiles in schizophrenia and affective psychoses.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Amphetamine; Amphetamine-Related Disorders; Austr | 2018 |
Mutual activation of glutamatergic mGlu
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Dizocilpine Maleate; Dose-Respon | 2018 |
Maternal immune activation in mid-late gestation alters amphetamine sensitivity and object recognition, but not other schizophrenia-related behaviours in adult rats.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Female; Male; Maternal Exposure; Mot | 2019 |
Schizophrenia dimension-specific antipsychotic drug action and failure in amphetamine-sensitized psychotic-like rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Disease Models, Animal; Dose-Re | 2018 |
Schizophrenia-related cognitive dysfunction in the Cyclin-D2 knockout mouse model of ventral hippocampal hyperactivity.
Topics: Amino Acids; Amphetamine; Animals; Attention; Behavior, Animal; Bridged Bicyclo Compounds, Heterocyc | 2018 |
A hypothesis arising from the epidemiology of schizophrenia in Maori.
Topics: Amphetamine; Hospitalization; Humans; Mental Health; Schizophrenia | 2019 |
Effect of estrous cycle on schizophrenia-like behaviors in MAM exposed rats.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Estrous Cycle; Female; Hippocampus; | 2019 |
Dopamine-mediated immunomodulation affects choroid plexus function.
Topics: Amphetamine; Animals; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervo | 2019 |
Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.
Topics: Amphetamine; Animals; Anxiety; Central Nervous System Sensitization; Diazepam; Dopaminergic Neurons; | 2013 |
Altered GSK3β signaling in an infection-based mouse model of developmental neuropsychiatric disease.
Topics: Amphetamine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glycogen Syn | 2013 |
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Topics: Allosteric Regulation; Amphetamine; Anilides; Animals; Antipsychotic Agents; Cyclohexanecarboxylic A | 2013 |
Hippocampal interneuron transplants reverse aberrant dopamine system function and behavior in a rodent model of schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Disease Models, Animal; Dopaminergic Neurons; Female; Hippo | 2013 |
The amphetamine sensitization model of schizophrenia symptoms and its effect on schedule-induced polydipsia in the rat.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Drinking; Drinking | 2014 |
Locomotor hyperactivity in 14-3-3ζ KO mice is associated with dopamine transporter dysfunction.
Topics: 14-3-3 Proteins; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Clozapine; Disease Mo | 2013 |
A novel analog of olanzapine linked to sarcosinyl moiety (PGW5) demonstrates high efficacy and good safety profile in mouse models of schizophrenia.
Topics: Alanine; Amphetamine; Animals; Antipsychotic Agents; Anxiety; Benzodiazepines; Brain; Central Nervou | 2014 |
Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Diazepam; Disea | 2014 |
An augmented dopamine system function is present prior to puberty in the methylazoxymethanol acetate rodent model of schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Agents; Dopamine | 2014 |
Effects of dehydroepiandrosterone in amphetamine-induced schizophrenia models in mice.
Topics: Adjuvants, Immunologic; Amphetamine; Animals; Apomorphine; Catalepsy; Central Nervous System Stimula | 2014 |
Animals with a schizophrenia-like phenotype are differentially sensitive to the motivational effects of cannabinoid agonists in conditioned place preference.
Topics: Amphetamine; Animals; Avoidance Learning; Benzoxazines; Cannabinoid Receptor Agonists; Conditioning, | 2014 |
A fundamental role for hippocampal parvalbumin in the dopamine hyperfunction associated with schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; | 2014 |
Cannabinoids reward sensitivity in a neurodevelopmental animal model of schizophrenia: a brain stimulation reward study.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Benzoxazines; Brain; Brain Injuries; C | 2014 |
Local inactivation of Gpr88 in the nucleus accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Cognition Disorders; Discrimination, Psycho | 2015 |
A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects.
Topics: Amphetamine; Animals; Antipsychotic Agents; Arrestins; beta-Arrestins; Brain; Catalepsy; Clathrin; G | 2014 |
Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.
Topics: Amphetamine; Animals; Attention; Benzoxazines; Cannabinoids; Central Nervous System Stimulants; Dise | 2014 |
Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study.
Topics: Adult; Amphetamine; Carbon Radioisotopes; Case-Control Studies; Dopamine; Dopamine Antagonists; Fema | 2015 |
[Amphetamine-induced psychosis or schizophrenia?].
Topics: Amphetamine; Amphetamine-Related Disorders; Central Nervous System Stimulants; Humans; Methamphetami | 2015 |
[Re: Amphetamine-induced psychosis or schizophrenia?].
Topics: Amphetamine; Amphetamine-Related Disorders; Central Nervous System Stimulants; Humans; Psychoses, Su | 2015 |
Mice Lacking the Serotonin Htr2B Receptor Gene Present an Antipsychotic-Sensitive Schizophrenic-Like Phenotype.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cohort Studies; Conditioning, Psychological; Cues; Disea | 2015 |
MAM (E17) rodent developmental model of neuropsychiatric disease: disruptions in learning and dysregulation of nucleus accumbens dopamine release, but spared executive function.
Topics: Amphetamine; Animals; Conditioning, Classical; Disease Models, Animal; Dopamine; Executive Function; | 2015 |
Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Avoidance Learning; Benzodiazepines; C | 2015 |
Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.
Topics: Amphetamine; Animals; Behavior, Animal; Benzodiazepines; Cognition Disorders; Dizocilpine Maleate; H | 2015 |
Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample.
Topics: Amphetamine; Disease Progression; Humans; Norway; Prospective Studies; Psychoses, Substance-Induced; | 2015 |
Combined behavioral studies and in vivo imaging of inflammatory response and expression of mGlu5 receptors in schnurri-2 knockout mice.
Topics: Acetamides; Amphetamine; Animals; Brain; Carbon Radioisotopes; Central Nervous System Stimulants; Ce | 2015 |
Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring.
Topics: Amphetamine; Animals; Autistic Disorder; Behavior, Animal; Cognition; Disease Models, Animal; Female | 2016 |
Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopamine; Dopamine Plasma Mem | 2016 |
Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.
Topics: Amphetamine; Animals; Antipsychotic Agents; Cyclopentanes; Disease Models, Animal; Dizocilpine Malea | 2016 |
Impaired hippocampal-dependent memory and reduced parvalbumin-positive interneurons in a ketamine mouse model of schizophrenia.
Topics: Amphetamine; Animals; Conditioning, Classical; Disease Models, Animal; Fear; Hippocampus; Interneuro | 2016 |
Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia.
Topics: Amphetamine; Animals; Anti-Inflammatory Agents; Central Nervous System Stimulants; Disease Models, A | 2016 |
Gabapentin prevents behavioral changes on the amphetamine-induced animal model of schizophrenia.
Topics: Amines; Amphetamine; Animals; Behavior, Animal; Calcium Channel Blockers; Cyclohexanecarboxylic Acid | 2016 |
Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Celecoxib; Disease Models, Animal; Drug Therapy, Comb | 2016 |
Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Amphetamine; Animals; Cognitive Dysfunct | 2016 |
Capturing schizophrenia-like prodromal symptoms in a spinocerebellar ataxia-17 transgenic rat.
Topics: Amphetamine; Animals; Disease Models, Animal; Male; Memory; Motor Activity; Prodromal Symptoms; Rats | 2017 |
Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Benzamides; Central Nervous Sys | 2009 |
A primate model of schizophrenia using chronic PCP treatment.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Uptake Inhibitors; Drug Adm | 2008 |
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Biological Availability; Brain; Catalepsy | 2009 |
Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.
Topics: Administration, Oral; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzazepines; Do | 2009 |
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.
Topics: Amphetamine; Animals; Antipsychotic Agents; Central Nervous System Stimulants; Clozapine; DNA Primer | 2008 |
D-aspartate prevents corticostriatal long-term depression and attenuates schizophrenia-like symptoms induced by amphetamine and MK-801.
Topics: Acoustic Stimulation; Amphetamine; Animals; Brain; Central Nervous System Stimulants; Cerebral Corte | 2008 |
Evaluating early preventive antipsychotic and antidepressant drug treatment in an infection-based neurodevelopmental mouse model of schizophrenia.
Topics: Age Factors; Amphetamine; Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Antip | 2010 |
Amphetamine in katatonia.
Topics: Amphetamine; Amphetamines; Humans; Schizophrenia | 1948 |
N-methyl-d-aspartic acid receptor antagonist-induced frequency oscillations in mice recreate pattern of electrophysiological deficits in schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Biological Clocks; Central Nervous | 2009 |
Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects.
Topics: Adult; alpha-Methyltyrosine; Amphetamine; Benzamides; Dopamine; Dopamine Uptake Inhibitors; Enzyme I | 2009 |
Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release.
Topics: Acetylcholine; alpha7 Nicotinic Acetylcholine Receptor; Amphetamine; Animals; Astrocytes; Central Ne | 2009 |
Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Antipsychotic Agents; Brain Chemistry; Disease | 2010 |
The amphetamine sensitization model of schizophrenia: relevance beyond psychotic symptoms?
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Conditioning, Operant; Di | 2009 |
Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate.
Topics: Acoustic Stimulation; Amphetamine; Animals; Brain; Disease Models, Animal; Dopamine; Electroencephal | 2009 |
Longitudinal MRI monitoring of brain damage in the neonatal ventral hippocampal lesion rat model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Brain; Central Nervous System Stimulants; Disease Mod | 2010 |
Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Clozapine; Disease Models, Animal; Male; Mice; Mice, Inb | 2009 |
Disruption of mesolimbic regulation of prefrontal cholinergic transmission in an animal model of schizophrenia and normalization by chronic clozapine treatment.
Topics: Acetylcholine; Aging; Amphetamine; Animals; Animals, Newborn; Clozapine; Disease Models, Animal; Hip | 2009 |
Clozapine administration in adolescence prevents postpubertal emergence of brain structural pathology in an animal model of schizophrenia.
Topics: Abnormalities, Drug-Induced; Age Factors; Amphetamine; Animals; Antipsychotic Agents; Attention; Bra | 2009 |
A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men.
Topics: Adolescent; Adult; Amphetamine; Animals; Bipolar Disorder; Disease Models, Animal; Dopamine Plasma M | 2009 |
Developmental vitamin D deficiency alters dopamine-mediated behaviors and dopamine transporter function in adult female rats.
Topics: Amphetamine; Animals; Behavior, Animal; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transpor | 2010 |
Constitutive genetic deletion of the growth regulator Nogo-A induces schizophrenia-related endophenotypes.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Antibodies; Brain; Central Nervous | 2010 |
Effect of amphetamine on extracellular concentrations of amino acids in striatum in neurotensin subtype 1 and 2 receptor null mice: a possible interaction between neurotensin receptors and amino acid systems for study of schizophrenia.
Topics: Amino Acids; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Extracellular | 2010 |
Enhanced dopamine function in DISC1-L100P mutant mice: implications for schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Brain Chemistry; | 2010 |
Schizophrenia, amphetamine-induced sensitized state and acute amphetamine exposure all show a common alteration: increased dopamine D2 receptor dimerization.
Topics: Aged; Amphetamine; Animals; Cells, Cultured; Dopamine; Dopamine Plasma Membrane Transport Proteins; | 2010 |
The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia.
Topics: Amphetamine; Animals; Basal Ganglia; Behavior, Animal; Brain; Corpus Striatum; Dopamine; Dopamine Ag | 2010 |
Socially isolated rats exhibit changes in dopamine homeostasis pertinent to schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Dopamine; Dopamine Agents; Homeostasis; Microdialysis; Motor | 2011 |
Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways.
Topics: Action Potentials; Amphetamine; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carrier | 2012 |
Hyperactivity of the hypothalamus-pituitary-adrenal axis in lipopolysaccharide-induced neurodevelopmental model of schizophrenia in rats: effects of antipsychotic drugs.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chlorpromazine; Clozapine; Corticosterone; Female; Front | 2011 |
Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Bicuculline; Cognition; Cues; Discrimination Learning; Dopam | 2011 |
Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats.
Topics: Amphetamine; Animals; Antipsychotic Agents; Chemical Phenomena; Disease Models, Animal; Dyskinesia, | 2011 |
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antipsychotic Agents; Anxiety; Behavior, Animal; Catalep | 2011 |
The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
Topics: Amphetamine; Animals; Antimanic Agents; Behavior, Animal; Cognition Disorders; Dizocilpine Maleate; | 2011 |
Effects of 5-HT6 antagonists, Ro-4368554 and SB-258585, in tests used for the detection of cognitive enhancement and antipsychotic-like activity.
Topics: Alzheimer Disease; Amphetamine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; F | 2011 |
Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Disease | 2012 |
Effects of risperidone and paliperidone pre-treatment on locomotor response following prenatal immune activation.
Topics: Amphetamine; Animals; Animals, Newborn; Antipsychotic Agents; Central Nervous System Stimulants; Dis | 2011 |
Vglut2 haploinsufficiency enhances behavioral sensitivity to MK-801 and amphetamine in mice.
Topics: Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimulants; Dizocilpine Maleate; Fema | 2011 |
A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Benzodiazepines; Diazepam; Disease Models, Animal; Dopa | 2011 |
Spontaneously Hypertensive Rats (SHR) present deficits in prepulse inhibition of startle specifically reverted by clozapine.
Topics: Acoustic Stimulation; Amphetamine; Animals; Antimanic Agents; Antipsychotic Agents; Carbamazepine; C | 2011 |
Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
Topics: Amphetamine; Animals; Benzodiazepines; Central Nervous System Stimulants; CHO Cells; Cognition Disor | 2012 |
NOGO-66 receptor deficient mice show slow acquisition of spatial memory task performance.
Topics: Alzheimer Disease; Amphetamine; Animals; Eating; Female; Fever; Hyperkinesis; Male; Maze Learning; M | 2012 |
Reversal of oxidative stress by histamine H₃ receptor-ligands in experimental models of schizophrenia.
Topics: Amphetamine; Animals; Antioxidants; Antipsychotic Agents; Apomorphine; Behavior, Animal; Brain Chemi | 2012 |
Fluoxetine and aripiprazole treatment following prenatal immune activation exert longstanding effects on rat locomotor response.
Topics: Acute-Phase Reaction; Amphetamine; Animals; Antipsychotic Agents; Aripiprazole; Disease Models, Anim | 2012 |
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
Topics: Allosteric Regulation; Amphetamine; Animals; Behavior, Animal; Brain; Disease Models, Animal; Dopami | 2013 |
Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy.
Topics: Adenine; Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; B-Lymphocytes; Blotting, | 2012 |
Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Astrocytes; Brain; Cell Line, Tran | 2013 |
Chronic hyperdopaminergic activity of schizophrenia is associated with increased ΔFosB levels and cdk-5 signaling in the nucleus accumbens.
Topics: Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Blotting, Western; Chroni | 2012 |
Striatal dopamine release in schizophrenia comorbid with substance dependence.
Topics: Adult; Amphetamine; Case-Control Studies; Corpus Striatum; Diagnosis, Dual (Psychiatry); Dopamine; F | 2013 |
Prior haloperidol, but not olanzapine, exposure augments the pursuit of reward cues: implications for substance abuse in schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Benzodiazepines; Conditioning, Classic | 2013 |
Hippocampal deep brain stimulation reverses physiological and behavioural deficits in a rodent model of schizophrenia.
Topics: Action Potentials; Amphetamine; Animals; Animals, Newborn; Attention Deficit Disorder with Hyperacti | 2013 |
A loss of hippocampal perineuronal nets produces deficits in dopamine system function: relevance to the positive symptoms of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Chondroitin ABC Lyase; Chondroitin Sulfate Proteoglycans | 2013 |
Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens.
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Cognition Disorders; Dopamine; Ma | 2002 |
Deficient prepulse inhibition of acoustic startle in Hooded-Wistar rats compared with Sprague-Dawley rats.
Topics: Acoustic Stimulation; Amphetamine; Animals; Anxiety; Apomorphine; Disease Models, Animal; Dizocilpin | 2003 |
Phencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Attention; Attention Deficit Disorder with Hyperactiv | 2003 |
Latent inhibition in 35-day-old rats is not an "adult" latent inhibition: implications for neurodevelopmental models of schizophrenia.
Topics: Aging; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Central Nervous System Stimulan | 2003 |
Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Calcineurin; Corpus Striatum; Disease Models, Animal; Dizoci | 2003 |
Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: a novel neurodevelopmental model of schizophrenia.
Topics: Aging; Amphetamine; Animals; Central Nervous System Stimulants; Clozapine; Corpus Striatum; Disease | 2003 |
Amphetamine sensitization of hallucinatory-like behaviors is dependent on prefrontal cortex in nonhuman primates.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Female; Hallucinations; Macaca mulatta; Mal | 2003 |
Differential role of serotonergic projections arising from the dorsal and median raphe nuclei in locomotor hyperactivity and prepulse inhibition.
Topics: 5,7-Dihydroxytryptamine; Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Behavior, | 2003 |
Perceptual accuracy in schizophrenia, depression, and neurosis, and effects of amytal.
Topics: Amobarbital; Amphetamine; Amphetamines; Barbiturates; Depression; Depressive Disorder; Humans; Neuro | 1956 |
[Study of the antagonistic psychopathological effects of lysergic acid monoethylamide (LAE-32) & methylphenylisopropylamine (pervitin)].
Topics: Amphetamine; Amphetamines; Hostility; Lysergic Acid; Lysergic Acid Diethylamide; Psychopathology; Sc | 1957 |
Experimental studies of the mental speed of schizophrenics. I. Effects of a stimulant and a depressant drug.
Topics: Amobarbital; Amphetamine; Amphetamines; Central Nervous System Stimulants; Humans; Learning; Schizop | 1958 |
Brain hexokinase activity. Investigation of brain tissue from rats receiving methamphetamine hydrochloride (Methedrine) and from schizophrenics.
Topics: Amphetamine; Amphetamines; Animals; Brain; Hexokinase; Methamphetamine; Phosphotransferases; Rats; S | 1960 |
REACTIONS TO USE OF AMPHETAMINES AS OBSERVED IN A PSYCHIATRIC HOSPITAL.
Topics: Alcoholism; Amobarbital; Amphetamine; Amphetamines; Barbiturates; Dextroamphetamine; Hospitals, Psyc | 1964 |
PSYCHOPHARMACOLOGIC SURVEY OF PSYCHIATRIC REFERRALS.
Topics: Amphetamine; Drug Therapy; Emotions; Hypnotics and Sedatives; Mental Disorders; Narcotics; Psychopha | 1964 |
OTHER ASPECTS OF DEPRESSION.
Topics: Alcoholism; Amphetamine; Antidepressive Agents; Barbiturates; Bipolar Disorder; Brain Diseases; Depr | 1965 |
TIME-SERIES, FREQUENCY ANALYSIS, AND ELECTROGENESIS OF THE EEGS OF NORMALS AND PSYCHOTICS BEFORE AND AFTER DRUGS.
Topics: Amphetamine; Antidepressive Agents; Barbiturates; Biomedical Research; Caffeine; Central Nervous Sys | 1965 |
COMPARISON OF AMPHETAMINE PSYCHOSIS AND SCHIZOPHRENIA.
Topics: Amphetamine; Amphetamines; Diagnosis, Differential; Hallucinations; Hallucinogens; Humans; Paranoid | 1965 |
Amphetamine-sensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Animals; Corpus Striatum; Disease Models, Animal; Dose-Response R | 2003 |
Anoxia at birth induced hyperresponsiveness to amphetamine and stress in postpubertal rats.
Topics: Amphetamine; Animals; Animals, Newborn; Brain; Cesarean Section; Dopamine; Dopamine Agents; Dose-Res | 2003 |
Intravenous pervitin and the psychopathology of schizophrenia.
Topics: Amphetamine; Humans; Psychopathology; Schizophrenia | 1951 |
[Therapeutic experiments in instinctivo-affective reorientation].
Topics: Amphetamine; Amphetamines; Convulsive Therapy; Humans; Schizophrenia | 1951 |
Psychopathology of schizophrenia and depression. I. Effect of amytal and amphetamine sulfate on level and maintenance of attention.
Topics: Aged; Amobarbital; Amphetamine; Attention; Depression; Depressive Disorder; Humans; Psychopathology; | 1952 |
Psychotomimetic effects of drugs--a common pathway to schizophrenia?
Topics: Amphetamine; Animals; Central Nervous System Agents; Corpus Striatum; Dopamine and cAMP-Regulated Ph | 2004 |
FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.
Topics: Amphetamine; Animals; Brain; Catalepsy; Chromatography, High Pressure Liquid; Disease Models, Animal | 2004 |
Very mild stress of pregnant rats reduces volume and cell number in nucleus accumbens of adult offspring: some parallels to schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Cell Count; Central Nervous System Stimulants; Disease M | 2004 |
T cell deficiency leads to cognitive dysfunction: implications for therapeutic vaccination for schizophrenia and other psychiatric conditions.
Topics: Amphetamine; Animals; Brain-Derived Neurotrophic Factor; Cognition; Cognition Disorders; Dizocilpine | 2004 |
Effect of adrenalectomy and corticosterone replacement on prepulse inhibition and locomotor activity in mice.
Topics: Adrenalectomy; Amphetamine; Animals; Corticosterone; Dose-Response Relationship, Drug; Haloperidol; | 2004 |
Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens.
Topics: Amphetamine; Animals; Animals, Newborn; Dopamine; Female; Nucleus Accumbens; Organ Size; Pregnancy; | 2004 |
Prenatal exposure of Long-Evans rats to 17alpha-ethinylestradiol modifies neither latent inhibition nor prepulse inhibition of the startle reflex but elicits minor deficits in exploratory behavior.
Topics: Amphetamine; Animals; Animals, Newborn; Avoidance Learning; Behavior, Animal; Brain; Conditioning, P | 2004 |
Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.
Topics: Amphetamine; Animals; Antipsychotic Agents; Disease Models, Animal; Dopamine; Dopamine Agents; Evoke | 2004 |
Delayed onset of prepulse inhibition deficits following kainic acid treatment on postnatal day 7 in rats.
Topics: Acoustic Stimulation; Age Factors; Amphetamine; Animals; Animals, Newborn; Apomorphine; Behavior, An | 2004 |
Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia.
Topics: Age Factors; Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Central Nervous System St | 2005 |
[Increasing prevalence of amphetamine--and methamphetamine-induced psychosis].
Topics: Amphetamine; Amphetamine-Related Disorders; Central Nervous System Stimulants; Cross-Sectional Studi | 2005 |
Effect of subchronic caffeine treatment on MK-801-induced changes in locomotion, cognition and ataxia in mice.
Topics: Adenosine; Amphetamine; Animals; Ataxia; Caffeine; Central Nervous System Stimulants; Cognition; Dis | 2005 |
A putative animal model of the "prodromal" state of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Anim | 2005 |
Sensitization to amphetamine, but not phencyclidine, disrupts prepulse inhibition and latent inhibition.
Topics: Amphetamine; Animals; Avoidance Learning; Conditioning, Psychological; Male; Mental Processes; Motor | 2005 |
Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia?
Topics: Amphetamine; Animals; Brain; Chromatography, High Pressure Liquid; Dopamine; Glutathione; Hallucinog | 2005 |
Sensitized attentional performance and Fos-immunoreactive cholinergic neurons in the basal forebrain of amphetamine-pretreated rats.
Topics: Amphetamine; Animals; Attention; Basal Nucleus of Meynert; Cell Count; Central Nervous System Stimul | 2005 |
Blockade of NMDA receptors in postnatal period decreased density of tyrosine hydroxylase immunoreactive axonal arbors in the medial prefrontal cortex of adult rats.
Topics: 2-Amino-5-phosphonovalerate; Amphetamine; Animals; Axons; Excitatory Amino Acid Antagonists; Female; | 2005 |
Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography.
Topics: Amphetamine; Animals; Brain; Bridged Bicyclo Compounds; Dopamine; Dopamine Agents; Dopamine Antagoni | 2006 |
Poisoning or primary nervous system disease?--difficulties of the differential diagnosis exemplified by four different clinical cases.
Topics: Acute Disease; Adolescent; Adult; Amphetamine; Antipsychotic Agents; Central Nervous System Stimulan | 2005 |
A schizophrenia-related sensorimotor deficit links alpha 3-containing GABAA receptors to a dopamine hyperfunction.
Topics: Amphetamine; Animals; Anti-Anxiety Agents; Diazepam; Disease Models, Animal; Dopamine; Electrophysio | 2005 |
Withdrawal from continuous amphetamine administration abolishes latent inhibition but leaves prepulse inhibition intact.
Topics: Acoustic Stimulation; Amphetamine; Animals; Disease Models, Animal; Inhibition, Psychological; Male; | 2006 |
A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Brain; Central Nervous System Stimulan | 2006 |
Antipsychotic pathway genes with expression altered in opposite direction by antipsychotics and amphetamine.
Topics: Amphetamine; Animals; Antipsychotic Agents; Brain; Brain Chemistry; Chromosome Mapping; Clozapine; D | 2006 |
Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.
Topics: Acoustic Stimulation; Amphetamine; Animals; Auditory Threshold; Brain Stem; Central Nervous System S | 2006 |
Antipsychotic-like profile of thioperamide, a selective H3-receptor antagonist in mice.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Catalepsy; Dose-Response Relationship, Drug | 2006 |
Scopolamine induces disruption of latent inhibition which is prevented by antipsychotic drugs and an acetylcholinesterase inhibitor.
Topics: Acetylcholine; Adrenergic Uptake Inhibitors; Amphetamine; Animals; Antipsychotic Agents; Attention; | 2007 |
The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia.
Topics: Amphetamine; Animals; Anxiety; Behavior, Animal; Catecholamines; Central Nervous System Stimulants; | 2007 |
Toward a neuro-cognitive animal model of the cognitive symptoms of schizophrenia: disruption of cortical cholinergic neurotransmission following repeated amphetamine exposure in attentional task-performing, but not non-performing, rats.
Topics: Acetylcholine; Amphetamine; Animals; Attention; Basal Nucleus of Meynert; Central Nervous System Sti | 2007 |
M4 agonists/5HT7 antagonists with potential as antischizophrenic drugs: serominic compounds.
Topics: Amphetamine; Animals; Antipsychotic Agents; Atropine; Brain; Chemistry, Pharmaceutical; Drug Design; | 2007 |
Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain.
Topics: Amphetamine; Animals; Autopsy; Brain; Disease Models, Animal; Dopamine; Dopamine Agents; Gene Expres | 2007 |
Evaluation of the mGlu8 receptor as a putative therapeutic target in schizophrenia.
Topics: Amphetamine; Animals; Anticonvulsants; Anxiety; Autoreceptors; Benzoates; Brain; Central Nervous Sys | 2007 |
Neuroleptic drugs revert the contextual fear conditioning deficit presented by spontaneously hypertensive rats: a potential animal model of emotional context processing in schizophrenia?
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Conditioning, Psychological; Disease M | 2009 |
Amphetamine sensitization in rats as an animal model of schizophrenia.
Topics: Acoustic Stimulation; Amphetamine; Analysis of Variance; Animals; Avoidance Learning; Behavior, Anim | 2008 |
Successful treatment of amphetamine addiction in a schizophrenic woman.
Topics: Adult; Amphetamine; Anticonvulsants; Anxiety; Depression; Electroconvulsive Therapy; Female; Humans; | 1967 |
Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").
Topics: Adult; Amphetamine; Animals; Depression; Dogs; Female; Humans; Male; Middle Aged; Monoamine Oxidase | 1967 |
Some new behaviour-disrupting amphetamines and their significance.
Topics: Amphetamine; Animals; Chemical Phenomena; Chemistry; Hallucinogens; Humans; Rats; Schizophrenia | 1967 |
Responses to apomorphine, amphetamine, and neuroleptics in schizophrenic subjects.
Topics: Adult; Amphetamine; Antipsychotic Agents; Apomorphine; Female; Humans; Male; Middle Aged; Psychiatri | 1980 |
Developments in biological psychiatry: clinical applications to the major psychoses.
Topics: Amphetamine; Antidepressive Agents; Depressive Disorder; Dexamethasone; Diagnosis, Differential; Hum | 1982 |
Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia.
Topics: Amphetamine; Autoantibodies; Autoimmune Diseases; Diseases in Twins; Dopamine Antagonists; HLA Antig | 1982 |
[Influence of lithium hydroxybutyrate on the electroencephalographic effects of fenamin].
Topics: Amphetamine; Animals; Bipolar Disorder; Cerebral Cortex; Chlorides; Disease Models, Animal; Drug Int | 1982 |
Limbic ictus and atypical psychoses.
Topics: Amphetamine; Animals; Carbamazepine; Cocaine; Electric Stimulation; Electroencephalography; Epilepsy | 1982 |
Hallucinatory behaviors in primates produced by around-the-clock amphetamine treatment for several days via implanted capsules.
Topics: Amphetamine; Animals; Behavior, Animal; Hallucinations; Hallucinogens; Haplorhini; Humans; Psychoses | 1983 |
Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats.
Topics: Amphetamine; Analysis of Variance; Animals; Attention; Conditioning, Psychological; Disease Models, | 1984 |
Isosafrole and schizophrenia-like psychosis.
Topics: Adult; Amphetamine; Dioxoles; Humans; Lysergic Acid Diethylamide; Male; Psychoses, Substance-Induced | 1984 |
Amphetamine challenge: effects in previously isolated rhesus monkeys and implications for animal models of schizophrenia.
Topics: Amphetamine; Animals; Brain; Disease Models, Animal; Humans; Individuality; Macaca mulatta; Schizoph | 1983 |
Animal models of schizophrenia.
Topics: Amphetamine; Animals; Animals, Newborn; Arousal; Attention; Disease Models, Animal; Hallucinogens; H | 1981 |
Amphetamine enhancement of reward asymmetry.
Topics: Amphetamine; Animals; Choice Behavior; Disease Models, Animal; Dopamine; Functional Laterality; Huma | 1981 |
Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors.
Topics: Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine; Dose-Re | 1995 |
Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Topics: Amphetamine; Animals; Antipsychotic Agents; Apomorphine; Butyrophenones; Dogs; Dopamine D2 Receptor | 1994 |
Nicotinic cholinergic normalization of amphetamine-induced loss of auditory gating in freely moving rats.
Topics: Amphetamine; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Evoked Potentials, A | 1995 |
Electrical sensitization of the meso-limbic dopaminergic system in rats: a pathogenetic model for schizophrenia.
Topics: Amphetamine; Animals; Apomorphine; Benzazepines; Disease Models, Animal; Dopamine D2 Receptor Antago | 1993 |
The sigma receptor ligand 1,3-di-(2-tolyl)guanidine in animal models of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Binding Sites; Dizocilpine Maleate; Guanidines; Male; Models | 1993 |
When does amphetamine-induced psychosis become schizophrenia?
Topics: Adult; Amphetamine; Amphetamines; Chronic Disease; Humans; Male; Psychoses, Substance-Induced; Schiz | 1996 |
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Topics: Adult; Amphetamine; Animals; Benzamides; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Hu | 1996 |
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Topics: Adult; Amphetamine; Animals; Benzamides; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Hu | 1996 |
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Topics: Adult; Amphetamine; Animals; Benzamides; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Hu | 1996 |
Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.
Topics: Adult; Amphetamine; Animals; Benzamides; Corpus Striatum; Dopamine; Dopamine Antagonists; Female; Hu | 1996 |
Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Diseases; Central Nervous System Stimulants; Disease M | 1996 |
A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls.
Topics: Adult; Amphetamine; Basal Ganglia; Benzamides; Binding Sites; Central Nervous System Stimulants; Cor | 1997 |
Cognitive impairment and substance abuse history as predictors of the temporal stability of negative symptoms in schizophrenia.
Topics: Adult; Age Factors; Amphetamine; Cocaine; Cognition Disorders; Comorbidity; Diagnosis, Dual (Psychia | 1997 |
Effects of dopamine depletion in the medial prefrontal cortex on the stress-induced increase in extracellular dopamine in the nucleus accumbens core and shell.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Disease Models, Animal; Dopamine; Dopamine Age | 1997 |
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Topics: Amphetamine; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine; Humans; Macaca mulatta; Micro | 1997 |
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Topics: Amphetamine; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine; Humans; Macaca mulatta; Micro | 1997 |
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Topics: Amphetamine; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine; Humans; Macaca mulatta; Micro | 1997 |
Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method.
Topics: Amphetamine; Animals; Carbon Radioisotopes; Corpus Striatum; Dopamine; Humans; Macaca mulatta; Micro | 1997 |
Prefrontal cortical and hippocampal modulation of dopamine-mediated effects.
Topics: Aging; Amphetamine; Animals; Animals, Newborn; Apomorphine; Disease Models, Animal; Dopamine; Halope | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort.
Topics: Adult; Amphetamine; Benzamides; Cohort Studies; Corpus Striatum; Dopamine; Female; Humans; Male; Mid | 1998 |
Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating.
Topics: Amphetamine; Analysis of Variance; Animals; Apomorphine; Dizocilpine Maleate; Dopamine; Dopamine Ago | 1999 |
Delusions, superstitious conditioning and chaotic dopamine neurodynamics.
Topics: Amphetamine; Animals; Conditioning, Psychological; Delusions; Disease Models, Animal; Dopamine; Huma | 1999 |
Neuroleptic influences on a lateralized behavioral bias in unoperated rats.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Female; Functional Laterality; Haloper | 1999 |
Dissociative effects of apomorphine infusions into the medial prefrontal cortex of rats on latent inhibition, prepulse inhibition and amphetamine-induced locomotion.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Central Nervous System Stimulants; Dopamine Ago | 1999 |
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia.
Topics: Adult; Amphetamine; Aspartic Acid; Carbon Radioisotopes; Corpus Striatum; Dopamine; Female; Humans; | 2000 |
The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion.
Topics: Amphetamine; Animals; Denervation; Disease Models, Animal; Dopamine; Hyperkinesis; Ibotenic Acid; Ma | 2000 |
Birth insult alters dopamine-mediated behavior in a precocial species, the guinea pig. Implications for schizophrenia.
Topics: Age Factors; Amphetamine; Animals; Apomorphine; Asphyxia Neonatorum; Behavior, Animal; Cesarean Sect | 2000 |
The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans.
Topics: Adult; Amphetamine; Attention Deficit Disorder with Hyperactivity; Benzamides; Carrier Proteins; Coc | 2001 |
Atypical antipsychotic effects of quetiapine fumarate in animal models.
Topics: Amphetamine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Clozapine; Disease Models, Anima | 2000 |
Effects of JL13, a pyridobenzoxazepine with potential atypical antipsychotic activity, in animal models for schizophrenia.
Topics: Amphetamine; Animals; Antipsychotic Agents; Benzodiazepinones; Central Nervous System Stimulants; Cl | 2001 |
Continuous phencyclidine treatment induces schizophrenia-like hyperreactivity of striatal dopamine release.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Central Nervous System Stimulants; Corpus Stri | 2001 |
Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less.
Topics: Adrenergic Uptake Inhibitors; Amphetamine; Animals; Animals, Newborn; Behavior, Animal; Denervation; | 2001 |
Latent inhibition, but not prepulse inhibition, is reduced during withdrawal from an escalating dosage schedule of amphetamine.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Disease Models, Animal; Inhibition, Psychol | 2001 |
Effects of reversible inactivation of the neonatal ventral hippocampus on behavior in the adult rat.
Topics: Age Factors; Aging; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Behavior, Animal; | 2002 |
Schizophrenia: the nature of the psychological disturbance and its possible neurochemcial basis.
Topics: Amphetamine; Antipsychotic Agents; Brain; Delusions; Diagnosis, Differential; Dopamine; Hallucinatio | 1979 |
Receptor sensitivity in schizophrenia.
Topics: Amphetamine; Animals; Behavior, Animal; Disease Models, Animal; Female; Humans; Rats; Rats, Inbred S | 1976 |
[Influence of extrapyramidal disorders induced by haloperidol on phenamine stereotypy and the effects of schizophrenic patients' serum (experimental study)].
Topics: Amphetamine; Animals; Basal Ganglia Diseases; Behavior; Behavior, Animal; Haloperidol; Humans; Immun | 1977 |
[Biological schizophrenia research].
Topics: Amphetamine; Dimethoxyphenylethylamine; Dopamine; Humans; Phenethylamines; Research; Schizophrenia | 1977 |
Non-random relation between drugs of abuse and psychiatric diagnosis.
Topics: Adult; Alcoholism; Amphetamine; Barbiturates; Depression; Hallucinogens; Heroin; Humans; Male; Menta | 1977 |
Electrophysiological (H-reflex) studies of patients with tardive dyskinesia.
Topics: Amphetamine; Apomorphine; Deanol; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Electr | 1977 |
Clinical response to several dopamine agonists in schizophrenic and nonschizophrenic subjects.
Topics: Amphetamine; Dextroamphetamine; Dopamine; Humans; Levodopa; Male; Paranoid Disorders; Piribedil; Psy | 1977 |
The evoked potential in pharmacopsychiatry.
Topics: Adult; Amphetamine; Antisocial Personality Disorder; Arousal; Auditory Cortex; Cerebral Cortex; Chil | 1977 |
Psychosocial dysfunctions as precursors to amphetamine abuse among adolescents.
Topics: Adolescent; Adult; Amphetamine; Antisocial Personality Disorder; Depression; Female; Humans; Male; M | 1976 |
Reduced growth hormone responses to amphetamine in "endogenous" depressive patients: studies in normal, "reactive" and "endogenous" depressive, schizophrenic, and chronic alcoholic subjects.
Topics: Adjustment Disorders; Adult; Aged; Alcoholism; Amphetamine; Blood Pressure; Chronic Disease; Depress | 1976 |
[Biochemical studies of schizophrenia].
Topics: Adenylyl Cyclase Inhibitors; Amphetamine; Brain; Dopamine; Haloperidol; Humans; Parkinson Disease; S | 1976 |
Amphetamine-induced dopaminergic hypersensitivity in guinea pigs. Implications in psychosis and human movement disorders.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Behavior, Animal; Disease Models, Animal; Dopamine Anta | 1975 |
Amphetamine psychosis: overview and a hypothesis.
Topics: Affective Symptoms; Amphetamine; Brain; Delusions; Depression, Chemical; Diagnosis, Differential; Do | 1975 |
Comparison of 3,4-dimethoxyphenylethylamine treated plasma from chronic schizophrenics and controls.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Amines; Blood; Brain Chemistry; Chronic Disease; Cr | 1975 |
[Release of dopamine and symptoms of schizophrenia].
Topics: Amphetamine; Dextroamphetamine; Dopamine; Humans; Methylphenidate; Norepinephrine; Schizophrenia | 1975 |
The dopamine hypothesis of schizophrenia. A critical analysis.
Topics: Acetylcholine; Amphetamine; Apomorphine; Cocaine; Dopamine; Electroconvulsive Therapy; gamma-Aminobu | 1975 |
The dopamine hypothesis of schizophrenia: focus on the dopamine receptor.
Topics: Amphetamine; Butyrophenones; Diagnosis, Differential; Dopamine; Humans; Models, Chemical; Phenothiaz | 1976 |
The history of schizophrenia research in Japan.
Topics: Amphetamine; Cohort Studies; Female; History, 19th Century; Humans; Japan; Male; Psychoses, Substanc | 1992 |
Computerized tomographic study on the brain of patients with alcohol dependence.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Withdrawal Delirium; Alcoholism; Amphetamine; Atrophy; Brain | 1991 |
Journal interview 27. Conversation with Philip Connell.
Topics: Adolescent; Adult; Amphetamine; Child; Confusion; Diagnosis, Differential; England; Humans; Illicit | 1990 |
Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.
Topics: Adolescent; Adult; Alcoholism; Amphetamine; Cross-Sectional Studies; Female; Humans; Incidence; Male | 1990 |
Amphetamine response and relapse risk after depot neuroleptic discontinuation.
Topics: Adult; Amphetamine; Antipsychotic Agents; Delayed-Action Preparations; Female; Fluphenazine; Humans; | 1985 |
Differential response to amphetamine in schizophrenia.
Topics: Adult; Amphetamine; Antipsychotic Agents; Arousal; Attention; Drug Therapy, Combination; Female; Hab | 1985 |
Amphetamine and chlorpromazine modify cerebral insulin levels in rats.
Topics: Amphetamine; Animals; Brain; Chlorpromazine; Disease Models, Animal; Female; Insulin; Rats; Rats, In | 1988 |
Are there state-dependent markers in schizophrenia?
Topics: Amphetamine; Apomorphine; Growth Hormone; Humans; Norepinephrine; Schizophrenia | 1985 |
Psychiatric problems of the aged.
Topics: Adjustment Disorders; Aged; Amphetamine; Antidepressive Agents; Antipsychotic Agents; Attitude of He | 1974 |
Neuropsychopharmacology of monoamines and their regulatory enzymes.
Topics: 5-Hydroxytryptophan; Amphetamine; Animals; Apomorphine; Biogenic Amines; Brain; Cocaine; Dextroamphe | 1974 |
Proceedings: Drugs, neurotransmitters, and psychosis.
Topics: Amphetamine; Antipsychotic Agents; Catecholamines; Humans; Phenothiazines; Receptors, Drug; Schizoph | 1974 |
Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
Topics: Amphetamine; Antipsychotic Agents; Brain; Butyrophenones; Disease Susceptibility; Dopamine; Dopamine | 1972 |
Personality characteristics of adolescent amphetamine users as measured by the MMPI.
Topics: Adolescent; Age Factors; Amphetamine; Educational Status; Family; Female; Humans; Male; MMPI; Ontari | 1974 |
New ways with hallucinogens.
Topics: Amphetamine; Hallucinogens; Humans; Mescaline; Phenethylamines; Schizophrenia | 1969 |
Dopamine and the pharmacology of schizophrenia: the state of the evidence.
Topics: Amphetamine; Animals; Brain; Cats; Caudate Nucleus; Chlorpromazine; Dogs; Dopamine; Haloperidol; Hap | 1974 |
Amphetamine abuse: a "speed" trap.
Topics: Adult; Affect; Amphetamine; Arousal; Body Weight; Diagnosis, Differential; Female; Hospitalization; | 1971 |
Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines.
Topics: Amphetamine; Animals; Brain; Brain Chemistry; Dopamine; Humans; Mice; Models, Biological; Models, Ps | 1973 |
Pharmacological and dynamic factors in psychotropic drug therapy.
Topics: Adult; Amphetamine; Antidepressive Agents; Antitubercular Agents; Anxiety; Bipolar Disorder; Chlorpr | 1970 |
Clinical and pharmacological investigation of a new psychotropic drug sulpiride (Dogmatil).
Topics: Adult; Amides; Amphetamine; Animals; Body Temperature; Central Nervous System Stimulants; Chlorproma | 1971 |
Proceedings: Effect of intravenous d-amphetamine, 1-amphetamine and methylphenidate in schizophrenics.
Topics: Amphetamine; Behavior; Dextroamphetamine; Hemodynamics; Humans; Methylphenidate; Psychiatric Status | 1974 |
Hallucinogenic drugs as precipitants of schizophrenia.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Cannabis; Drug Interactions; Female; Hallucinogens; Hum | 1974 |
Amphetamine psychosis: behavioral and biochemical aspects.
Topics: Adolescent; Adult; Affect; Alcoholism; Amphetamine; Brain; Cognition Disorders; Delusions; Depressio | 1974 |
Brain dopamine and behaviour. A critical analysis of the relationship between dopamine antagonism and therapeutic efficacy of neuroleptic drugs.
Topics: Amphetamine; Animals; Arousal; Brain; Chlorpromazine; Corpus Striatum; Dopamine; Dopamine Antagonist | 1974 |
A two factor theory of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Bipolar Disorder; Brain; Dextroamphetamine; Dopamine; Dose-Resp | 1974 |
Dopamine antagonism and antischizophrenic potency of neuroleptic drugs.
Topics: Amphetamine; Animals; Behavior, Animal; Brain Chemistry; Chlorpromazine; Dopamine Antagonists; Human | 1973 |
Symposium on catecholamines and their enzymes in the neuropathology of schizophrenia. Epilogue.
Topics: Amphetamine; Autopsy; Brain; Catecholamines; Dopamine; Dopamine Antagonists; Drug Tolerance; Fluores | 1974 |
The difference between the experienced reality of hallucinations in young drug abusers and schizophrenic patients.
Topics: Adolescent; Adult; Amphetamine; Auditory Perception; Cannabis; Ethanol; Female; Hallucinations; Hall | 1972 |
Childhood asociality in the differential diagnosis of schizophrenia with drug abuse vs. psychosis with drug intoxication.
Topics: Achievement; Adolescent; Adult; Amphetamine; Attitude to Health; Cannabis; Diagnosis, Differential; | 1973 |
[Modern drugs and schizophrenia].
Topics: Amphetamine; Cannabis; Female; Humans; Lysergic Acid Diethylamide; Male; Opium; Psychoses, Substance | 1973 |
Interaction of low-dose amphetamine use with schizophrenia in outpatients: three case reports.
Topics: Acute Disease; Adult; Ambulatory Care; Amphetamine; Dextroamphetamine; Dose-Response Relationship, D | 1974 |
Treatment of compulsive eating disturbances with anticonvulsant medication.
Topics: Adolescent; Adult; Amphetamine; Anorexia Nervosa; Body Image; Body Weight; Compulsive Behavior; Depr | 1974 |
Chronic hallucinogenic drug use and thought disturbance.
Topics: Adolescent; Adult; Amphetamine; Cannabis; Chronic Disease; Cognition Disorders; Female; Hallucinogen | 1972 |
A case of Gilles de la Tourette's syndrome occurring in New Zealand.
Topics: Adolescent; Amphetamine; Barbiturates; Humans; Male; Mental Disorders; New Zealand; Schizophrenia; S | 1970 |
[Use of a combination of methionine and various psychotropic drugs in the treatment of chronic schizophrenia patients].
Topics: Amphetamine; Chronic Disease; Humans; Iproniazid; Methionine; Monoamine Oxidase Inhibitors; Schizoph | 1969 |
[The pharmacologic properties and therapeutic effectiveness of the new antidepressant preparation Azaphen].
Topics: Adult; Aged; Amphetamine; Animals; Antidepressive Agents; Bipolar Disorder; Cats; Depression; Depres | 1969 |
Drug abuse in a young psychiatric population.
Topics: Adolescent; Adult; Age Factors; Amphetamine; Barbiturates; Cannabis; Ethnicity; Family Characteristi | 1970 |
[The effect of phenamine on medicinal parkinsonism and retardation of movement upon stimulation of the caudate nucleus (a clinico-experimental study)].
Topics: Amphetamine; Caudate Nucleus; Female; Haloperidol; Humans; Male; Parkinson Disease; Parkinson Diseas | 1970 |
[Clinical method and its modification for differential diagnosis of neuroses and neurosis-like conditions].
Topics: Amphetamine; Diagnosis, Differential; Humans; Neurotic Disorders; Schizophrenia | 1970 |
Amphetamines, barbiturates, LSD and cannabis: their use and misuse.
Topics: Amphetamine; Barbiturates; Cannabis; Child Behavior Disorders; Crime; Depression; Humans; Hyperkines | 1970 |
Neuroleptics in the treatment of schizophrenia.
Topics: Amphetamine; Animals; Behavior; Behavior, Animal; Humans; Phenmetrazine; Psychoses, Substance-Induce | 1970 |
Chromosomal aberrations in users of psychoactive drugs.
Topics: Amphetamine; Cannabis; Chromosome Aberrations; Drug Synergism; Female; Heroin; Humans; Lysergic Acid | 1971 |
[Basic research in schizophrenia].
Topics: Adrenal Glands; Amphetamine; Chemical Phenomena; Chemistry; Dopamine; Female; Hirsutism; Humans; Mon | 1971 |
Amphetamine abuse by hospitalized chronic schizophrenic patients.
Topics: Amphetamine; Chromatography, Thin Layer; Chronic Disease; Hospitalization; Hospitals, Psychiatric; H | 1968 |
Amphetamine use and abuse in psychiatric patients.
Topics: Adolescent; Adult; Amphetamine; California; Chromatography, Thin Layer; Drug Utilization; Female; Ho | 1968 |
An influence of blood plasma from schizophrenics on an action of 3,4-dimethoxyphenylethylamine.
Topics: Amphetamine; Animals; Central Nervous System; Crowding; Humans; Mice; Monoamine Oxidase Inhibitors; | 1968 |
Characteristics of drug abusers admitted to a psychiatric hospital.
Topics: Adult; Age Factors; Amphetamine; Antisocial Personality Disorder; Antitussive Agents; Barbiturates; | 1968 |
[Psychoses in chronic ephedrine addiction].
Topics: Adult; Amphetamine; Diagnosis, Differential; Ephedrine; Female; Humans; Male; Middle Aged; Psychoses | 1968 |
The role of maribuana in patterns of drug abuse by adolescents.
Topics: Adolescent; Adult; Aggression; Amphetamine; Barbiturates; Cannabis; Catatonia; Chronic Disease; Diss | 1969 |
Psychiatric complications of amphetamine substances.
Topics: Adolescent; Adult; Amitriptyline; Amphetamine; Chlordiazepoxide; Depression; Ephedrine; Female; Hall | 1966 |
[Changes in the Color Pyramid Test induced by amphetamine shock in a group of schizophrenics].
Topics: Adult; Amphetamine; Female; Humans; Male; Prognosis; Psychological Tests; Schizophrenia; Schizophren | 1966 |